Etoposide

Search with Google Search with Bing

Information
Drug Name
Etoposide
Description
Entry(CIViC)
4
CIViC
Disease Mutation EL ET ED CS VO TR Pubmed Links
stomach carcinoma TP53 p.Arg273Cys (p.R273C)
( ENST00000420246.6, ENST00000269305.9, ENST00000359597.8, ENST00000413465.6, ENST00000445888.6, ENST00000455263.6, ENST00000504290.5, ENST00000504937.5, ENST00000510385.5, ENST00000576024.2, ENST00000604348.6, ENST00000610292.4, ENST00000610538.4, ENST00000610623.4, ENST00000618944.4, ENST00000619186.4, ENST00000619485.4, ENST00000620739.4, ENST00000622645.4, ENST00000714356.1, ENST00000714357.1, ENST00000714359.1, ENST00000714408.1, ENST00000714409.1 ) TP53 p.Arg273Cys (p.R273C)
( ENST00000269305.9, ENST00000359597.8, ENST00000413465.6, ENST00000420246.6, ENST00000445888.6, ENST00000455263.6, ENST00000504290.5, ENST00000504937.5, ENST00000510385.5, ENST00000576024.2, ENST00000604348.6, ENST00000610292.4, ENST00000610538.4, ENST00000610623.4, ENST00000618944.4, ENST00000619186.4, ENST00000619485.4, ENST00000620739.4, ENST00000622645.4, ENST00000714356.1, ENST00000714357.1, ENST00000714359.1, ENST00000714408.1, ENST00000714409.1 )
C Predictive Does Not Support Sensitivity/Response Somatic 3 14514923 Detail
stomach carcinoma TP53 p.Tyr220Cys (p.Y220C)
( ENST00000510385.5, ENST00000504937.5, ENST00000604348.6, ENST00000576024.2, ENST00000269305.9, ENST00000714409.1, ENST00000359597.8, ENST00000413465.6, ENST00000420246.6, ENST00000445888.6, ENST00000455263.6, ENST00000504290.5, ENST00000610292.4, ENST00000610538.4, ENST00000610623.4, ENST00000618944.4, ENST00000619186.4, ENST00000619485.4, ENST00000620739.4, ENST00000622645.4, ENST00000714356.1, ENST00000714357.1, ENST00000714359.1, ENST00000714408.1 ) TP53 p.Tyr220Cys (p.Y220C)
( ENST00000618944.4, ENST00000610623.4, ENST00000269305.9, ENST00000359597.8, ENST00000413465.6, ENST00000420246.6, ENST00000445888.6, ENST00000455263.6, ENST00000504290.5, ENST00000504937.5, ENST00000510385.5, ENST00000576024.2, ENST00000604348.6, ENST00000610292.4, ENST00000610538.4, ENST00000619186.4, ENST00000619485.4, ENST00000620739.4, ENST00000622645.4, ENST00000714356.1, ENST00000714357.1, ENST00000714359.1, ENST00000714408.1, ENST00000714409.1 )
C Predictive Supports Sensitivity/Response Somatic 3 14514923 Detail
stomach cancer TP53 OVEREXPRESSION
( ENST00000269305.9 ) TP53 OVEREXPRESSION
( ENST00000269305.9 )
B Predictive Supports Sensitivity/Response Somatic 4 14514923 Detail
stomach carcinoma TP53 DELETERIOUS MUTATION TP53 DELETERIOUS MUTATION C Predictive Supports Sensitivity/Response Somatic 1 14514923 Detail
Annotation
Description Associated Genes Associated Variants Sensitivity Supported Source Links
A female patient taking part in a 25 patient gastr... TP53 TP53 p.Arg273Cys (p.R273C)
( ENST00000420246.6, ENST00000269305.9, ENST00000359597.8, ENST00000413465.6, ENST00000445888.6, ENST00000455263.6, ENST00000504290.5, ENST00000504937.5, ENST00000510385.5, ENST00000576024.2, ENST00000604348.6, ENST00000610292.4, ENST00000610538.4, ENST00000610623.4, ENST00000618944.4, ENST00000619186.4, ENST00000619485.4, ENST00000620739.4, ENST00000622645.4, ENST00000714356.1, ENST00000714357.1, ENST00000714359.1, ENST00000714408.1, ENST00000714409.1 ) TP53 p.Arg273Cys (p.R273C)
( ENST00000269305.9, ENST00000359597.8, ENST00000413465.6, ENST00000420246.6, ENST00000445888.6, ENST00000455263.6, ENST00000504290.5, ENST00000504937.5, ENST00000510385.5, ENST00000576024.2, ENST00000604348.6, ENST00000610292.4, ENST00000610538.4, ENST00000610623.4, ENST00000618944.4, ENST00000619186.4, ENST00000619485.4, ENST00000620739.4, ENST00000622645.4, ENST00000714356.1, ENST00000714357.1, ENST00000714359.1, ENST00000714408.1, ENST00000714409.1 )
Sensitivity false CIViC Evidence detail
A male patient taking part in a 25 patient gastric... TP53 TP53 p.Tyr220Cys (p.Y220C)
( ENST00000510385.5, ENST00000504937.5, ENST00000604348.6, ENST00000576024.2, ENST00000269305.9, ENST00000714409.1, ENST00000359597.8, ENST00000413465.6, ENST00000420246.6, ENST00000445888.6, ENST00000455263.6, ENST00000504290.5, ENST00000610292.4, ENST00000610538.4, ENST00000610623.4, ENST00000618944.4, ENST00000619186.4, ENST00000619485.4, ENST00000620739.4, ENST00000622645.4, ENST00000714356.1, ENST00000714357.1, ENST00000714359.1, ENST00000714408.1 ) TP53 p.Tyr220Cys (p.Y220C)
( ENST00000618944.4, ENST00000610623.4, ENST00000269305.9, ENST00000359597.8, ENST00000413465.6, ENST00000420246.6, ENST00000445888.6, ENST00000455263.6, ENST00000504290.5, ENST00000504937.5, ENST00000510385.5, ENST00000576024.2, ENST00000604348.6, ENST00000610292.4, ENST00000610538.4, ENST00000619186.4, ENST00000619485.4, ENST00000620739.4, ENST00000622645.4, ENST00000714356.1, ENST00000714357.1, ENST00000714359.1, ENST00000714408.1, ENST00000714409.1 )
Sensitivity true CIViC Evidence detail
In a Phase II trial of 25 patients with metastaic ... TP53 TP53 OVEREXPRESSION
( ENST00000269305.9 ) TP53 OVEREXPRESSION
( ENST00000269305.9 )
Sensitivity true CIViC Evidence detail
In a study of 25 patients with advanced gastric ca... TP53 TP53 DELETERIOUS MUTATION TP53 DELETERIOUS MUTATION Sensitivity true CIViC Evidence detail
The tumor suppressor SNF5, the core subunit of SWI... SMARCB1 SMARCB1 UNDEREXPRESSION Resitance or Non-Reponse true MMMP detail
Antagonistic combinations with imexon included eto... ROS1 ROS1 OVEREXPRESSION Resitance or Non-Reponse true MMMP detail
In melanoma cells with high MAGE-A expression, tri... HDAC9 HDAC9 UNDEREXPRESSION Sensitivity true MMMP detail
Valproate chemosensitizes melanoma in association ... HDAC9 HDAC9 UNDEREXPRESSION Sensitivity true MMMP detail
ATM silencing inhibits apoptosis induced by etopos... ATM ATM UNDEREXPRESSION Resitance or Non-Reponse true MMMP detail
Synergistic antitumor activity of etoposide and hu... IL1R1 IL1R1 OVEREXPRESSION Sensitivity true MMMP detail
Milk fat globule EGF-8 promotes melanoma progressi... MFGE8 MFGE8 EXPRESSION Resitance or Non-Reponse true MMMP detail
PAF activates NFkB which leads to upregulation of ... PCLAF PCLAF EXPRESSION Resitance or Non-Reponse true MMMP detail
YB-1 is a transcription/translation factor regulat... YBX1 YBX1 UNDEREXPRESSION Sensitivity true MMMP detail
Forced expression of transcription factor E2F1 (vi... E2F1 E2F1 OVEREXPRESSION Sensitivity true MMMP detail
Decreasing levels of p53 mRNA correlated with incr... TP53 TP53 EXPRESSION Sensitivity true MMMP detail
The sensitivity of melanoma cell lines to daunomyc... ABCC1 ABCC1 EXPRESSION Resitance or Non-Reponse true MMMP detail
Lowering the GSTP1 level significantly increased (... GSTP1 GSTP1 UNDEREXPRESSION Sensitivity true MMMP detail
Combined inhibition of both GSTP1 and MRP1 (ABCC1)... GSTP1 GSTP1 UNDEREXPRESSION Sensitivity true MMMP detail
Reduced expression is associated with resistance a... GSDME GSDME EXPRESSION Sensitivity true MMMP detail
Decreased expression associated with resistance MLH1 MLH1 EXPRESSION Sensitivity true MMMP detail
Decreased expression associated with resistance MSH2 MSH2 EXPRESSION Sensitivity true MMMP detail
Using primary cultures derived from melanoma patie... BIRC7 BIRC7 EXPRESSION Resitance or Non-Reponse true MMMP detail
The acquisition of the mutant allele of topoisomer... TOP2A TOP2A UNKNOWN Resitance or Non-Reponse true MMMP detail
c-Myc is able to sensitize human melanoma cells to... MYC MYC OVEREXPRESSION Sensitivity true MMMP detail
Using melanoma cells expressing or not expressing ... APAF1 APAF1 EXPRESSION Sensitivity true MMMP detail
NCT ID Status Phase Summary Start date Completion date
NCT03458260 Active, not recruiting Phase 2 Study of Pixantrone in CD20+ Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma March 26, 2018 March 2025
NCT03017326 Active, not recruiting Phase 3 Paediatric Hepatic International Tumour Trial August 24, 2017 August 1, 2027
NCT02262325 Active, not recruiting Phase 2 Hypofractionated Boost Before Chemoradiation for Patients With Stage II-III Non-small Cell Lung Cancer Unsuitable for Surgery June 8, 2015 December 31, 2024
NCT03016871 Active, not recruiting Phase 2 Nivolumab, Ifosfamide, Carboplatin, and Etoposide as Second-Line Therapy in Treating Patients With Refractory or Relapsed HL April 24, 2017 January 30, 2026
NCT00077285 Active, not recruiting Phase 2 Irinotecan and Carboplatin as Upfront Window Therapy in Treating Patients With Newly Diagnosed Intermediate-Risk or High-Risk Rhabdomyosarcoma October 2003 October 2024
NCT02794571 Active, not recruiting Phase 1 Safety and Pharmacokinetics (PK) of Escalating Doses of Tiragolumab as a Single Agent and in Combination With Atezolizumab and/or Other Anti-Cancer Therapies in Locally Advanced or Metastatic Tumors May 23, 2016 October 5, 2024
NCT00792948 Active, not recruiting Phase 2 Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia September 1, 2009 January 6, 2025
NCT00470223 Active, not recruiting Phase 3 Combined Chemotherapy With or Without Zoledronic Acid for Patients With Osteosarcoma March 2007 December 2026
NCT04256421 Active, not recruiting Phase 3 A Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Patients With Untreated Extensive-Stage Small Cell Lung Cancer February 4, 2020 April 15, 2026
NCT02227199 Active, not recruiting Phase 1/Phase 2 Brentuximab Vedotin, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma October 10, 2014 September 30, 2025
NCT00476190 Active, not recruiting Phase 2 ALL Adult Consortium Trial: Adult ALL Trial April 2007 December 2024
NCT02213913 Active, not recruiting Phase 1/Phase 2 Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphomas July 29, 2014 July 29, 2023
NCT03984448 Active, not recruiting Phase 2/Phase 3 Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas October 22, 2019 April 1, 2028
NCT03407144 Active, not recruiting Phase 2 Safety and Efficacy of Pembrolizumab (MK-3475) in Children and Young Adults With Classical Hodgkin Lymphoma (MK-3475-667/KEYNOTE-667) April 9, 2018 February 13, 2027
NCT02481310 Active, not recruiting Phase 1/Phase 2 Combination Chemotherapy, Rituximab, and Ixazomib Citrate in Treating Patients With Non-Hodgkin Lymphoma October 28, 2015 July 2024
NCT03382561 Active, not recruiting Phase 2 Cisplatin/Carboplatin and Etoposide With or Without Nivolumab in Treating Patients With Extensive Stage Small Cell Lung Cancer May 2, 2018 December 31, 2024
NCT03064867 Active, not recruiting Phase 1/Phase 2 Venetoclax Plus R-ICE Chemotherapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma June 26, 2017 August 12, 2023
NCT00869232 Active, not recruiting Phase 2 UARK 2008-02 A Trial for High-risk Myeloma Evaluating Accelerating and Sustaining Complete Remission October 2008 October 2024
NCT03004287 Active, not recruiting Phase 2 2015-12: A Study Exploring the Use of Early and Late Consolidation/Maintenance Therapy July 1, 2017 October 2025
NCT00871013 Active, not recruiting Phase 2 Trial for Patients Not Qualifying for TT4 and TT5 Protocols Because of Prior Therapy March 2009 December 2024
NCT00878254 Active, not recruiting Phase 2 Rituximab and Combination Chemotherapy in Treating Patients With Previously Untreated Mantle Cell Lymphoma March 25, 2009 September 2027
NCT02176967 Active, not recruiting Phase 3 Response and Biology-Based Risk Factor-Guided Therapy in Treating Younger Patients With Non-high Risk Neuroblastoma August 8, 2014 September 30, 2026
NCT05224141 Active, not recruiting Phase 3 Pembrolizumab/Vibostolimab (MK-7684A) or Atezolizumab in Combination With Chemotherapy in First Line Treatment of Extensive-Stage Small Cell Lung Cancer (MK-7684A-008, KEYVIBE-008) March 24, 2022 June 7, 2027
NCT02443077 Active, not recruiting Phase 3 Ibrutinib Before and After Stem Cell Transplant in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma October 12, 2016 May 10, 2025
NCT02166463 Active, not recruiting Phase 3 Brentuximab Vedotin and Combination Chemotherapy in Treating Children and Young Adults With Stage IIB, Stage IIIB, IVA, or IVB Hodgkin Lymphoma March 19, 2015 September 22, 2024
NCT05192889 Active, not recruiting Phase 1/Phase 2 Trial Treating Relapsed Acute Lymphoblastic Leukemia With Venetoclax and Navitoclax August 25, 2022 July 2029
NCT04101357 Active, not recruiting Phase 1/Phase 2 Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT411 June 19, 2020 July 2024
NCT02153580 Active, not recruiting Phase 1 Cellular Immunotherapy Following Chemotherapy in Treating Patients With Recurrent Non-Hodgkin Lymphomas, Chronic Lymphocytic Leukemia, or B-Cell Prolymphocytic Leukemia September 24, 2014 December 31, 2024
NCT04774380 Active, not recruiting Phase 3 Study of Durvalumab in Combination With Platinum and Etoposide for the First Line Treatment of Patients With Extensive-stage Small Cell Lung Cancer November 11, 2021 December 31, 2024
NCT03937843 Active, not recruiting Phase 2 Reduced Intensity Radio-chemotherapy for Stage IIA/B Seminoma July 29, 2019 December 31, 2046
NCT02661503 Active, not recruiting Phase 3 HD21 for Advanced Stages July 2016 September 2025
NCT00526396 Active, not recruiting Phase 3 STAD-1 Small Cell Lung Cancer Toxicity Adjusted Dosing Study September 2007 December 2023
NCT02114229 Active, not recruiting Phase 2 Phase 2 Study of Alisertib Therapy for Rhabdoid Tumors May 14, 2014 September 2027
NCT03043872 Active, not recruiting Phase 3 Durvalumab ± Tremelimumab in Combination With Platinum Based Chemotherapy in Untreated Extensive-Stage Small Cell Lung Cancer (CASPIAN) March 27, 2017 December 31, 2024
NCT00534430 Active, not recruiting Phase 2 Busulfan, Etoposide, and Total-Body Irradiation in Treating Patients Undergoing Donor Stem Cell or Bone Marrow Transplant for Advanced Hematologic Cancer February 29, 2000 December 30, 2024
NCT02112916 Active, not recruiting Phase 3 Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma October 4, 2014 September 22, 2024
NCT00534469 Active, not recruiting Phase 2 Auto BMT for Non-M3 AML in 1st Remission in Pts </=60y of Age Using Busulfan/FTBI & VP16 as a Prep R February 8, 2000 December 30, 2024
NCT02101853 Active, not recruiting Phase 3 Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia December 17, 2014 September 22, 2024
NCT02632708 Active, not recruiting Phase 1 Safety Study of AG-120 or AG-221 in Combination With Induction and Consolidation Therapy in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) With an IDH1 and/or IDH2 Mutation December 31, 2015 July 2024
NCT02628405 Active, not recruiting Phase 1/Phase 2 R-ICE and Lenalidomide in Treating Patients With First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma May 20, 2016 December 20, 2025
NCT02402920 Active, not recruiting Phase 1 Pembrolizumab and Concurrent Chemoradiotherapy or Radiation Therapy in Treating Patients With Small Cell Lung Cancer July 22, 2015 July 31, 2025
NCT03786783 Active, not recruiting Phase 2 Dinutuximab, Sargramostim, and Combination Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma March 4, 2019 September 22, 2024
NCT04472949 Active, not recruiting Phase 2 Thoracic Radiotherapy Plus Maintenance Durvalumab After First Line Carboplatin and Etoposide Plus Durvalumab in Extensive-stage Disease Small Cell Lung Cancer (ED-SCLC). June 25, 2021 December 2027
NCT00544115 Active, not recruiting Phase 2 Donor Peripheral Stem Cell Transplant in Treating Patients With Advanced Hematologic Cancer or Other Disorders October 16, 2001 December 30, 2024
NCT00092222 Active, not recruiting Phase 2 Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity October 28, 2004 October 1, 2025
NCT03164057 Active, not recruiting Phase 2 A Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia June 15, 2017 June 2027
NCT03749018 Active, not recruiting Phase 2 Nivolumab With DA-REPOCH Chemotherapy Regimen in Treating Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma January 2, 2019 July 31, 2024
NCT03586999 Active, not recruiting Phase 1/Phase 2 Nivolumab With Standard of Care Chemotherapy for Peripheral T Cell Lymphomas November 7, 2018 December 2024
NCT04951115 Active, not recruiting Phase 2 A Trial With Chemotherapy, Immunotherapy, and Radiotherapy for Patients With Newly Diagnosed Stage IV Small Cell Lung Cancer July 12, 2021 July 1, 2025
NCT02003222 Active, not recruiting Phase 3 Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia May 19, 2014 December 4, 2024
NCT00554788 Active, not recruiting Phase 3 Combination Chemotherapy, Autologous Stem Cell Transplant, and/or Radiation Therapy in Treating Young Patients With Extraocular Retinoblastoma February 4, 2008 December 31, 2024
NCT02595424 Active, not recruiting Phase 2 Cisplatin, Carboplatin and Etoposide or Temozolomide and Capecitabine in Treating Patients With Neuroendocrine Carcinoma of the Gastrointestinal Tract or Pancreas That Is Metastatic or Cannot Be Removed by Surgery April 6, 2016 January 1, 2029
NCT00557193 Active, not recruiting Phase 3 Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia January 15, 2008 June 28, 2024
NCT03141359 Active, not recruiting Phase 2 Use of High Dose Radiation Followed by Chemotherapy and Radiation to Treat Locally Advanced NSCLC May 12, 2017 July 2027
NCT01085617 Active, not recruiting Phase 3 Standard Chemotherapy With or Without Nelarabine or Rituximab in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia December 2010 December 2025
NCT01096368 Active, not recruiting Phase 3 Maintenance Chemotherapy or Observation Following Induction Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Ependymoma May 7, 2010 September 22, 2024
NCT00334815 Active, not recruiting Phase 2 Combination Chemotherapy, Radiation Therapy, and Bevacizumab in Treating Patients With Newly Diagnosed Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery June 15, 2006 February 22, 2025
NCT02964013 Active, not recruiting Phase 1 Study of Vibostolimab Alone and in Combination With Pembrolizumab in Advanced Solid Tumors (MK-7684-001) ( KEYVIBE-001) December 13, 2016 August 1, 2024
NCT00104676 Active, not recruiting Phase 3 Combination Chemotherapy in Treating Patients With Stage II or Stage III Germ Cell Tumors November 26, 2003 December 2024
NCT00572169 Active, not recruiting Phase 3 UARK 2006-66, Total Therapy 3B: An Extension of UARK 2003-33 Total Therapy November 2006 August 2025
NCT05091567 Active, not recruiting Phase 3 A Phase III, Open-Label Study of Maintenance Lurbinectedin in Combination With Atezolizumab Compared With Atezolizumab in Participants With Extensive-Stage Small-Cell Lung Cancer November 18, 2021 March 6, 2026
NCT00576979 Active, not recruiting Phase 1/Phase 2 Intensity-Modulated Radiation Therapy, Etoposide, and Cyclophosphamide Followed By Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia March 4, 2008 December 30, 2024
NCT00336024 Active, not recruiting Phase 3 Combination Chemotherapy Followed By Peripheral Stem Cell Transplant in Treating Young Patients With Newly Diagnosed Supratentorial Primitive Neuroectodermal Tumors or High-Risk Medulloblastoma August 6, 2007 December 31, 2028
NCT03568994 Active, not recruiting Early Phase 1 Atovaquone (Mepron®) Combined With Conventional Chemotherapy for de Novo Acute Myeloid Leukemia (AML) July 10, 2018 October 31, 2025
NCT04745689 Active, not recruiting Phase 2 Study of AZD2811 + Durvalumab in ES-SCLC February 23, 2021 March 31, 2023
NCT02553460 Active, not recruiting Phase 1/Phase 2 Total Therapy for Infants With Acute Lymphoblastic Leukemia (ALL) I January 29, 2016 October 2031
NCT01993810 Active, not recruiting Phase 3 Comparing Photon Therapy To Proton Therapy To Treat Patients With Lung Cancer February 3, 2014 October 2025
NCT00110110 Active, not recruiting Phase 2 Combination Chemotherapy and Cyclosporine Followed by Focal Therapy for Bilateral Retinoblastoma June 2004 December 31, 2024
NCT04665856 Active, not recruiting Phase 3 Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Participants With Untreated Extensive-Stage Small Cell Lung Cancer December 22, 2020 April 15, 2025
NCT04092283 Active, not recruiting Phase 3 Testing the Addition of an Antibody to Standard Chemoradiation Followed by the Antibody for One Year to Standard Chemoradiation Followed by One Year of the Antibody in Patients With Unresectable Stage III Non-Small Cell Lung Cancer April 29, 2020 December 31, 2028
NCT03117751 Active, not recruiting Phase 2/Phase 3 Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma March 29, 2017 March 31, 2028
NCT02896582 Active, not recruiting Phase 2 Efficacy of Upfront and Maintenance Obinutuzumab in Mantle Cell Lymphoma Treated by DHAP and MRD Driven Maintenance October 2016 March 2025
NCT02521493 Active, not recruiting Phase 3 Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome December 23, 2015 June 30, 2024
NCT02342782 Active, not recruiting Phase 1 Yttrium Y 90 Basiliximab and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With Mature T-cell Non-Hodgkin Lymphoma June 8, 2020 December 31, 2024
NCT01231906 Active, not recruiting Phase 3 Combination Chemotherapy in Treating Patients With Non-Metastatic Extracranial Ewing Sarcoma November 22, 2010
NCT02883049 Active, not recruiting Phase 3 Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations February 29, 2012 September 22, 2024
NCT05309629 Active, not recruiting Phase 2 Safety and Efficacy Study of First-line Treatment With QL1706 Plus Chemotherapy in Extensive-Stage Small Cell Lung Cancer April 18, 2022 November 1, 2024
NCT01959698 Active, not recruiting Phase 1 Carfilzomib, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Stage I-IV Diffuse Large B-cell Lymphoma April 17, 2014 June 1, 2025
NCT04730999 Active, not recruiting Phase 2 Efficacy and Safety Study of a New Therapeutic Strategy in the Treatment of Extended-Disease Small-Cell Lung Cancer July 1, 2020 October 17, 2024
NCT02338518 Active, not recruiting Phase 3 Comparison of SEEOX and SOX Regimens in Stage ⅢB/ⅢC Gastric Cancer Patients January 4, 2015 October 2023
NCT03567642 Active, not recruiting Phase 1 A Study of the Combination of Osimertinib, Platinum and Etoposide for Patients With Metastatic EGFR Mutant Lung Cancers June 12, 2018 June 2024
NCT02337985 Active, not recruiting Phase 1 Gene Therapy and Combination Chemotherapy in Treating Patients With AIDS-Related Non-Hodgkin Lymphoma November 20, 2015 December 31, 2024
NCT02329080 Active, not recruiting Phase 2 New Combination of Chemoimmunotherapy for Systemic B-cell Lymphoma With Central Nervous System Involvement December 2014 December 2023
NCT00632853 Active, not recruiting Phase 3 Radiation Therapy Regimens in Treating Patients With Limited-Stage Small Cell Lung Cancer Receiving Cisplatin and Etoposide March 2008
NCT01946529 Active, not recruiting Phase 2 Therapeutic Trial for Patients With Ewing Sarcoma Family of Tumor and Desmoplastic Small Round Cell Tumors December 27, 2013 July 2026
NCT01371981 Active, not recruiting Phase 3 Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia June 20, 2011 September 30, 2027
NCT00379340 Active, not recruiting Phase 3 Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Newly Diagnosed Stage III or Stage IV Wilms' Tumor February 26, 2007
NCT01920932 Active, not recruiting Phase 2 Adcetris (Brentuximab Vedotin), Combination Chemotherapy, and Radiation Therapy in Treating Younger Patients With Stage IIB, IIIB and IV Hodgkin Lymphoma August 12, 2013 May 2028
NCT00641381 Active, not recruiting Phase 1 Carmustine, Etoposide, Cyclophosphamide, and Stem Cell Transplant in Treating Patients With HIV-Associated Lymphoma May 10, 2000 December 30, 2024
NCT03850067 Active, not recruiting Phase 1 A Safety, Tolerability and Preliminary Efficacy Evaluation of CC-90011 Given in Combination With Cisplatin and Etoposide in Subjects With First Line, Extensive Stage Small Cell Lung Cancer March 12, 2019 June 26, 2024
NCT01873326 Active, not recruiting Phase 2 Paclitaxel, Ifosfamide and Cisplatin (TIP) Versus Bleomycin, Etoposide and Cisplatin (BEP) for Patients With Previously Untreated Intermediate- and Poor-risk Germ Cell Tumors June 2013 June 2024
NCT04047862 Active, not recruiting Phase 1 Study of Ociperlimab (BGB-A1217) in Combination With Tislelizumab in Advanced Solid Tumors August 26, 2019 August 2024
NCT03113500 Active, not recruiting Phase 2 Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell Lymphoma May 25, 2017 December 21, 2024
NCT04380636 Active, not recruiting Phase 3 Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012) July 6, 2020 February 15, 2027
NCT03533582 Active, not recruiting Phase 2/Phase 3 Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery May 24, 2018 June 30, 2026
NCT03020030 Active, not recruiting Phase 3 Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and Adolescents March 3, 2017 November 2034
NCT01871766 Active, not recruiting Phase 2 Risk-Adapted Focal Proton Beam Radiation and/or Surgery in Patients With Low, Intermediate and High Risk Rhabdomyosarcoma Receiving Standard or Intensified Chemotherapy December 4, 2013 June 2030
NCT01476839 Active, not recruiting Phase 1 Radiolabeled Monoclonal Antibody Therapy and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With Primary Refractory or Relapsed Hodgkin Lymphoma November 9, 2012 December 31, 2024
NCT02306161 Active, not recruiting Phase 3 Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma December 12, 2014 September 22, 2024
NCT01864109 Active, not recruiting Phase 2 Irinotecan and Temozolomide in Combination With Existing High Dose Alkylator Based Chemotherapy for Treatment of Patients With Newly Diagnosed Ewing Sarcoma May 2013 May 2027
NCT01857934 Active, not recruiting Phase 2 Therapy for Children With Advanced Stage Neuroblastoma July 5, 2013 December 2024
NCT03980925 Active, not recruiting Phase 2 Platinum-doublet Chemotherapy and Nivolumab for the Treatment of Subjects With Neuroendocrine Neoplasms (NENs) of the Gastroenteropancreatic (GEP) Tract or of Unknown (UK) Origin. October 11, 2019 December 2023
NCT01511562 Active, not recruiting Phase 2 Combination Chemotherapy With or Without Autologous Stem Cell Transplant in Treating Patients With Central Nervous System B-Cell Lymphoma September 2012
NCT03517137 Active, not recruiting Phase 2 Very Early PET-response Adapted Targeted Therapy for Advanced Hodgkin Lymphoma: a Single -Arm Phase II Study August 1, 2019 November 16, 2026
NCT04665765 Active, not recruiting Phase 2 Polatuzumab Vedotin, Rituximab, Ifosfamide, Carboplatin, and Etoposide (PolaR-ICE) as Initial Salvage Therapy for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma January 18, 2021 March 31, 2024
NCT03944772 Active, not recruiting Phase 2 Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD) June 25, 2019 May 6, 2025
NCT01840566 Active, not recruiting Phase 1 High Dose Therapy and Autologous Stem Cell Transplantation Followed by Infusion of Chimeric Antigen Receptor (CAR) Modified T-Cells Directed Against CD19+ B-Cells for Relapsed and Refractory Aggressive B Cell Non-Hodgkin Lymphoma April 2013 April 2025
NCT03077828 Active, not recruiting Phase 2 Pembrolizumab and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma April 21, 2017 December 2024
NCT04924101 Active, not recruiting Phase 2 Efficacy and Safety of Pembrolizumab Plus Investigational Agents in Combination With Chemotherapy as First-Line Treatment in Extensive-Stage Small Cell Lung Cancer (ES-SCLC) (MK-3475-B99/ KEYNOTE-B99) July 15, 2021 July 14, 2026
NCT01798004 Active, not recruiting Phase 1 Busulfan, Melphalan, and Stem Cell Transplant After Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma April 8, 2013
NCT03811002 Active, not recruiting Phase 3 Testing the Addition of a New Immunotherapy Drug, Atezolizumab (MPDL3280A), to the Usual Chemoradiation (CRT) Therapy Treatment for Limited Stage Small Cell Lung Cancer (LS-SCLC) July 26, 2019 December 28, 2026
NCT02815592 Active, not recruiting Phase 1 Trial of BMS-986012 in Combination With Platinum and Etoposide November 28, 2016 June 3, 2024
NCT01602666 Active, not recruiting Phase 2 Chemotherapy Followed by Radiation Therapy in Treating Younger Patients With Newly Diagnosed Localized Central Nervous System Germ Cell Tumors June 27, 2012 June 30, 2024
NCT00716066 Active, not recruiting Phase 2 Autologous Stem Cell Transplant for Neurologic Autoimmune Diseases June 2008 January 31, 2030
NCT04293562 Active, not recruiting Phase 3 A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations July 21, 2020 September 30, 2027
NCT01783535 Active, not recruiting Phase 2 Protocol for the Study and Treatment of Participants With Intraocular Retinoblastoma June 19, 2013 January 2028
NCT05008224 Active, not recruiting Phase 2 Study of Safety and Efficacy of Pembrolizumab and Chemotherapy in Participants With Newly Diagnosed Classical Hodgkin Lymphoma (cHL) (MK-3475-C11/KEYNOTE-C11) October 7, 2021 May 22, 2024
NCT02797470 Active, not recruiting Phase 1/Phase 2 Gene Therapy in Treating Patients With Human Immunodeficiency Virus-Related Lymphoma Receiving Stem Cell Transplant June 23, 2016 June 30, 2025
NCT04622228 Active, not recruiting Phase 2 Study of Low-Dose Radiotherapy (LDRT) Concurrent Cisplatin/Carboplatin Plus Etoposide With Atezolizumab for Patients With Extensive-Stage Small Cell Lung Cancer December 16, 2020 June 30, 2024
NCT03467256 Active, not recruiting Phase 1/Phase 2 CD19 T-CAR for Treatment of Children and Young Adults With r/r B-ALL May 14, 2018 October 15, 2025
NCT00003727 Completed Phase 2 Chemotherapy and Peripheral Stem Cell Transplantation Followed by Immunotherapy in Treating Patients With Chronic Myelogenous Leukemia March 1999 February 2008
NCT04028050 Completed Phase 3 A Study of Atezolizumab in Combination With Carboplatin Plus Etoposide to Investigate Safety and Efficacy in Patients With Untreated Extensive-Stage Small Cell Lung Cancer August 12, 2019 July 13, 2023
NCT00003783 Completed Phase 2 Combination Chemotherapy in Treating Children With Very High Risk Acute Lymphocytic Leukemia March 1999 March 2007
NCT00003811 Completed Phase 2 Combination Chemotherapy Plus Amifostine in Treating Children With Malignant Germ Cell Tumors April 2000 September 2007
NCT00003812 Completed Phase 2 Chemotherapy Plus Radiation Therapy in Treating Patients With Limited-Stage Small Cell Lung Cancer March 1999 March 2006
NCT03991884 Completed Phase 1 Inotuzumab Ozogamicin and Chemotherapy in Treating Patients With Recurrent or Refractory B-cell Acute Lymphoblastic Leukemia September 24, 2019 June 28, 2023
NCT00003816 Completed Phase 2/Phase 3 Combination Chemotherapy and Donor Stem Cell Transplant in Treating Patients With Aplastic Anemia or Hematologic Cancer October 19, 1998 July 12, 2019
NCT00003859 Completed Phase 3 Surgery Plus Radiation Therapy With or Without Chemotherapy in Treating Children With Primitive Neuroectodermal Tumors of the CNS April 1992 April 2003
NCT00003860 Completed Phase 2 Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Small Cell Lung Cancer September 1998 September 2005
NCT00003875 Completed Phase 2 Busulfan and Etoposide Followed by Peripheral Blood Stem Cell Transplant and Low-Dose Aldesleukin in Treating Patients With Acute Myeloid Leukemia October 13, 1998 June 11, 2015
NCT00003935 Completed Phase 1 Combination Chemotherapy Plus Radiation Therapy in Treating Children With Newly Diagnosed Brain Stem Glioma September 1999 March 2007
NCT00003937 Completed Phase 3 Combination Chemotherapy Plus Dexrazoxane in Treating Patients With Newly Diagnosed Nonmetastatic Osteosarcoma September 1999 June 2008
NCT00003941 Completed Phase 3 Combination Chemotherapy With or Without Peripheral Stem Cell Transplant in Treating Men With Previously Untreated Germ Cell Cancer April 1999
NCT00003957 Completed Phase 2 Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Relapsed Non-Hodgkin's Lymphoma December 1998 August 2001
NCT00003967 Completed Phase 1 Topotecan Plus Etoposide in Treating Patients With Recurrent Ovarian, Peritoneal, or Fallopian Tube Cancer September 1999
NCT00003996 Completed Phase 2 Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme May 1999 May 2008
NCT00004006 Completed Phase 2 Combination Chemotherapy, Radiation Therapy, and Bone Marrow Transplantation in Treating Patients With Retinoblastoma November 1997 September 2005
NCT00004010 Completed Phase 2 Combination Chemotherapy and Radiation Therapy in Treating Children With Previously Untreated Stage II, Stage III, or Stage IV Hodgkin's Disease October 1999 June 2008
NCT00004031 Completed Phase 3 SWOG-9704 Chemoradiotherapy and Peripheral Stem Cell Transplantation Compared With Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma July 1997 October 31, 2013
NCT00004054 Completed Phase 3 Hormone Therapy Plus Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Prostate Cancer January 2000 November 2013
NCT00004061 Completed Phase 2 Biological Therapy in Treating Patients Undergoing Radiation Therapy, Chemotherapy, and Peripheral Stem Cell Transplantation for Hematologic Cancer May 1999 December 2009
NCT00004110 Completed Phase 2 Monoclonal Antibody Therapy Plus Etoposide in Treating Patients With Neuroblastoma August 1999
NCT00004132 Completed Phase 2 Growth Factor to Prevent Oral Mucositis in Patients With Hematologic Cancer January 2000 May 2004
NCT00004169 Completed Phase 2 Chemotherapy, Radiation Therapy, and Peripheral Stem Cell Transplantation in Treating Patients With Hodgkin's Disease November 1993 January 2007
NCT00004176 Completed Phase 2 Amifostine, Chemotherapy, and Radiation Therapy in Treating Patients With Limited-Stage Small Cell Lung Cancer October 1998 February 2001
NCT00004186 Completed Phase 1/Phase 2 Combination Chemotherapy in Treating Patients With Small Cell Lung Cancer December 1996 December 2004
NCT00004188 Completed Phase 3 Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Neuroblastoma February 2001
NCT00004192 Completed Phase 2 Colony-Stimulating Factors to Relieve Neutropenia in Patients With Recurrent Non-Hodgkin's Lymphoma May 1, 2000 March 16, 2001
NCT00004224 Completed Phase 2 Combination Chemotherapy Followed by Radiation Therapy in Treating Children With Localized Ependymoma January 1999 March 2008
NCT00004898 Completed Phase 1/Phase 2 Radiation Therapy and Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With High-Grade Lymphoma or Acute Lymphoblastic Leukemia October 1999 July 2003
NCT00004899 Completed Phase 2 Chemotherapy Plus Bone Marrow Transplantation and Filgrastim in Treating Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome October 1999 August 2004
NCT00004900 Completed Phase 2 Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Women With Metastatic Breast Cancer October 1999 August 2004
NCT00004904 Completed Phase 1 Stem Cell Transplantation in Treating Patients With Hematologic Cancer October 1999 July 2000
NCT00004905 Completed Phase 2 Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Chronic Myelogenous Leukemia or Acute Leukemia October 1999 September 2004
NCT00004906 Completed Phase 2 Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Women With Metastatic Breast Cancer October 1999 June 2001
NCT00004907 Completed Phase 1/Phase 2 Chemotherapy and Radiation Therapy Plus Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Relapsed or Refractory T-cell Lymphoma, Hodgkin's Lymphoma, or Non-Hodgkin's Lymphoma October 1999 August 2004
NCT00005022 Completed Phase 1 Radiation Therapy Plus Combination Chemotherapy in Treating Patients With Small Cell Lung Cancer February 1998 June 2010
NCT03901118 Completed Phase 2 Chiauranib in Combination With Chemotherapy in Patients With Ovarian Cancer July 1, 2019 December 18, 2020
NCT00005578 Completed Phase 3 Combination Chemotherapy With or Without Dexrazoxane in Treating Children With Hodgkin's Disease March 1997 June 2008
NCT00005589 Completed Phase 3 Combination Chemotherapy Plus Peripheral Stem Cell Transplantation With or Without Rituximab in Treating Patients With Relapsed Non-Hodgkin's Lymphoma October 1999 April 2013
NCT00005613 Completed Phase 2 Peripheral Stem Cell Transplantation in Treating Patients With Non-Hodgkin's Lymphoma or Hodgkin's Disease March 1996 June 2010
NCT00005631 Completed Phase 2 Rituximab and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Large Cell Lymphoma November 1999 November 2002
NCT00005793 Completed Phase 1/Phase 2 A Phase I/II Study of Induction Chemotherapy With Daunorubicin, Cytarabine, Topotecan and Etoposide July 1999 November 2006
NCT00005802 Completed Phase 1/Phase 2 Chemotherapy Followed by Donor White Blood Cells Plus Interleukin-2 in Treating Patients With Acute Myeloid or Lymphocytic Leukemia June 1999 March 2005
NCT00005803 Completed Phase 1/Phase 2 Autologous Stem Cell Transplant Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoma September 1999 October 2018
NCT00005823 Completed Phase 3 Intensive Compared With Nonintensive Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome December 1998 December 2007
NCT00005863 Completed Phase 3 Combination Chemotherapy With or Without Filgrastim and/or Tretinoin in Treating Patients With Acute Myeloid Leukemia August 1998 December 2004
NCT00005867 Completed Phase 3 Combination Chemotherapy in Treating Patients With Aggressive Non-Hodgkin's Lymphoma January 1998 August 2007
NCT00005946 Completed Phase 1 Chemotherapy Plus Donor White Blood Cell Infusion in Treating Patients With Relapsed Hematologic Cancer Following Donor Peripheral Stem Cell Transplantation October 2000 June 2002
NCT00005964 Completed Phase 2 Comparison of Two Combination Chemotherapy Regimens in Treating Patients With Previously Untreated Aggressive Stage II, Stage III, or Stage IV Non-Hodgkin's Lymphoma May 2000 March 2006
NCT00005977 Completed Phase 3 Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma or Acute Lymphocytic Leukemia September 2000 September 2006
NCT00005978 Completed Phase 1 N99-01: Combination Chemotherapy, Radiation Therapy, and Stem Cell Transplantation in Treating Patients With Neuroblastoma May 2000
NCT00005985 Completed Phase 2 Filgrastim and Chemotherapy Followed by Peripheral Stem Cell Transplant in Treating Patients With Hodgkin's Lymphoma or Non-Hodgkin's Lymphoma August 2000 February 2007
NCT03794167 Completed Phase 2 BuCE Versus BuME as Conditioning Therapy in Non-Hodgkin's Lymphoma June 1, 2012 November 30, 2018
NCT03792815 Completed Phase 2 Busulfan, Melphalan and Etoposide as Conditioning for Autologous Transplantation for Non-Hodgkin's Lymphoma (NHL) October 2009 September 2013
NCT00006012 Completed Phase 1/Phase 2 Combination Chemotherapy and Radiation Therapy in Treating Patients With Limited-Stage Small Cell Lung Cancer February 2001 May 2006
NCT00006040 Completed Phase 1 Radiolabeled Monoclonal Antibody Therapy and Etoposide Followed by Peripheral Stem Cell Transplantation in Treating Patients With Advanced Myelodysplastic Syndrome or Refractory Leukemia April 2000 November 2003
NCT03582475 Completed Phase 1 Pembrolizumab With Combination Chemotherapy in Treating Participants With Locally Advanced or Metastatic Small Cell/Neuroendocrine Cancers of Urothelium or Prostate December 20, 2018 May 16, 2022
NCT00006122 Completed Phase 2 Gemtuzumab Ozogamicin With or Without Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia June 2000
NCT00006184 Completed Phase 2 Chemotherapy, Stem Cell Transplantation and Donor and Patient Vaccination for Treatment of Multiple Myeloma February 8, 2001 January 12, 2008
NCT00006258 Completed Phase 2 Combination Chemotherapy Followed by Radiation Therapy in Treating Patients With Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumor, or Ependymoma November 1997 January 2005
NCT00006260 Completed Phase 2 Combination Chemotherapy in Treating Patients With Metastatic Breast Cancer May 1997
NCT00006363 Completed Phase 3 Combination Chemotherapy With or Without PSC 833, Peripheral Stem Cell Transplantation, and/or Interleukin-2 in Treating Patients With Acute Myeloid Leukemia November 2000
NCT00006373 Completed Phase 2 Combination Chemotherapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Non-Hodgkin's Lymphoma or Hodgkin's Lymphoma February 2000 December 2011
NCT00006455 Completed Phase 3 Combination Chemotherapy in Treating Children With Anaplastic Large Cell Lymphoma (ALCL 99) November 26, 1999 September 3, 2020
NCT00006461 Completed Phase 3 Combination Chemotherapy Followed by Second-Look Surgery and Radiation Therapy in Treating Children With Nonmetastatic Medulloblastoma or Primitive Neuroectodermal Tumor October 2000
NCT00006487 Completed Phase 1 S0004: Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Limited-stage Small Cell Lung Cancer October 2000 July 2004
NCT00006695 Completed Phase 2 Monoclonal Antibody Therapy, Combination Chemotherapy, and Peripheral Stem Cell Transplant in Non-Hodgkin's Lymphoma April 1, 2000 December 16, 2014
NCT00006734 Completed Phase 3 Comparison of Combination Chemotherapy Regimens in Treating Patients With Ewing's Sarcoma or Neuroectodermal Tumor May 2001 June 30, 2023
NCT00006747 Completed Phase 2 Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Mantle Cell Lymphoma November 2000 February 2003
NCT00007813 Completed Phase 1 Peripheral Stem Cell Transplantation Plus Chemotherapy in Treating Patients With Malignant Solid Tumors May 31, 1997 February 1, 2005
NCT00007852 Completed Phase 2 Rituximab & Combination Chemotherapy Followed by Transplantation in Relapsed or Refractory Non-Hodgkin's Lymphoma September 1, 2000 January 1, 2011
NCT00007865 Completed Phase 2 Combination Chemotherapy Plus Rituximab in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma September 1, 2000 April 22, 2008
NCT00007982 Completed Phase 2 Chemotherapy Plus Peripheral Stem Cell Transplant in Treating Patients With Central Nervous System Cancer April 1999 May 2008
NCT00008190 Completed Phase 2 Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation and Interleukin-2 in Treating Patients With Acute Leukemia March 1999 May 2008
NCT00012051 Completed Phase 3 Chemotherapy and Peripheral Stem Cell Transplant With or Without Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma September 2000 October 2007
NCT03432598 Completed Phase 2 Anti-PD-1 in Combination With Chemotherapy as First-Line Treatment to Lung Cancer August 24, 2017 December 21, 2020
NCT00017225 Completed Phase 2 Chemotherapy and Radiation Therapy With or Without Peripheral Stem Cell Transplantation in Treating Patients With Neuroblastoma May 1997 February 2002
NCT00017251 Completed Phase 1 Combination Chemotherapy Plus Oblimersen in Treating Patients With Previously Untreated Extensive-Stage Small Cell Lung Cancer April 2001
NCT00017368 Completed Phase 2 Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Neuroblastoma April 2001 January 2012
NCT00018954 Completed Phase 2 Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia and Diffuse Non-Hodgkin's Lymphoma October 1992 October 2002
NCT03328104 Completed Phase 1 Everolimus in Combination With Nelarabine, Cyclophosphamide and Etoposide in Lymphoblastic Leukemia/Lymphoma July 24, 2018 June 29, 2023
NCT00020709 Completed Phase 3 Combination Chemotherapy and Radiation Therapy With or Without Gefitinib in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery June 2001
NCT00020943 Completed Phase 2 Chemotherapy and Rituximab With Peripheral Stem Cell Transplantation in Treating Patients With Mantle Cell Lymphoma June 2001 September 2009
NCT00022737 Completed Phase 3 Combination Chemotherapy With or Without Peripheral Stem Cell Transplant in Treating Children With Acute Lymphoblastic Leukemia October 2002
NCT00023998 Completed Phase 2 Chemotherapy With or Without Trastuzumab in Treating Patients With Metastatic Osteosarcoma July 2001 May 2007
NCT03161054 Completed Phase 2 Metronomic Chemotherapy in Elderly Non-fit Patients With Aggressive B-Cell Lymphomas September 12, 2017 June 21, 2021
NCT03132532 Completed Phase 2 Platinum Doublet Chemotherapy and Proton Beam Radiation Therapy in Treating Patients With Stage II-III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery July 31, 2017 December 31, 2023
NCT00025259 Completed Phase 3 Chemotherapy With or Without Additional Chemotherapy and/or Radiation Therapy in Treating Children With Newly Diagnosed Hodgkin's Disease September 2002
NCT00025272 Completed Phase 2 Combination Chemotherapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer November 1, 2001 January 18, 2005
NCT03118466 Completed Phase 2 Mitoxantrone, Etoposide, and Cytarabine (MEC) Plus Lenalidomide for Relapsed or Refractory Acute Myeloid Leukemia September 25, 2017 August 18, 2021
NCT00025363 Completed Phase 2 Comparison of Chemotherapy Regimens in Treating Children With Relapsed or Progressive Rhabdomyosarcoma November 2001
NCT00025428 Completed Phase 3 Combination Chemotherapy Before Surgery in Treating Children With Localized Neuroblastoma December 2000 November 2013
NCT00025441 Completed Phase 2 Combination Chemotherapy in Treating Children With Metastatic Rhabdomyosarcoma or Other Malignant Mesenchymal Tumors November 1998 March 2010
NCT00025597 Completed Phase 2 Combination Chemotherapy Followed by Surgery in Treating Infants With Newly Diagnosed Neuroblastoma. July 1999 February 2011
NCT00025610 Completed Phase 2 Combination Chemotherapy in Treating Infants With Newly Diagnosed Neuroblastoma July 1999 March 2009
NCT00025623 Completed Phase 2 Combination Chemotherapy Followed by Surgery in Treating Infants With Newly Diagnosed Neuroblastoma July 1999 March 2009
NCT00025649 Completed Phase 2 Combination Chemotherapy Followed by Surgery and Peripheral Stem Cell or Bone Marrow Transplantation in Treating Infants With Newly Diagnosed Neuroblastoma July 1999 March 2009
NCT00026208 Completed Phase 2 Combination Chemotherapy Plus Low-Dose Radiation Therapy in Treating Patients With Stage I or Stage IIA Hodgkin's Lymphoma June 2001 February 13, 2017
NCT00027846 Completed Phase 2 Observation or Radiation Therapy and/or Chemotherapy and Second Surgery in Treating Children Who Have Undergone Surgery for Ependymoma August 2003 March 31, 2016
NCT00027898 Completed Phase 1 Bortezomib and Combination Chemotherapy in Treating Patients With Advanced Solid Tumors January 2002
NCT00028665 Completed Phase 2 Cyclophosphamide W/or W/Out Rituximab and Peripheral Stem Cell Transplantation in Patients With Recurrent Non-Hodgkin's Lymphoma June 2000
NCT00028769 Completed Phase 2 S0032, Combination Chemotherapy Plus Hormone Therapy in Treating Patients With Metastatic Prostate Cancer December 2001 July 2011
NCT03072771 Completed Phase 1 Blinatumomab Consolidation Post Autologous Stem Cell Transplantation in Patients With Diffuse Large B-Cell Lymphoma (DLBCL) August 1, 2017 October 30, 2023
NCT00032019 Completed Phase 2 Combination Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma February 2002 April 2009
NCT03066778 Completed Phase 3 A Study of Pembrolizumab (MK-3475) in Combination With Etoposide/Platinum (Cisplatin or Carboplatin) for Participants With Extensive Stage Small Cell Lung Cancer (MK-3475-604/KEYNOTE-604) May 2, 2017 September 21, 2021
NCT00033696 Completed Phase 2 Combination Chemotherapy and Radiation Therapy in Treating Patients With Limited-Stage Small Cell Lung Cancer September 2001 April 2009
NCT00039130 Completed Phase 2 Rituximab, Chemotherapy, and Filgrastim in Treating Patients With Burkitt's Lymphoma or Burkitt's Leukemia May 2002 October 2014
NCT00039195 Completed Phase 2 Chemotherapy and Rituximab With or Without Total-Body Irradiation and Peripheral Stem Cell Transplant in Treating Patients With Lymphoma November 2006 January 2010
NCT00039377 Completed Phase 2 Chemotherapy, Imatinib Mesylate, and Peripheral Stem Cell Transplantation in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia April 2002 February 2014
NCT00040690 Completed Phase 2 Combination Chemotherapy in Treating Patients With Burkitt's Lymphoma or Burkitt's Leukemia November 2008 December 2008
NCT00040872 Completed Phase 2 Multiple Therapies in Treating Patients With Advanced Neuroblastoma June 2000 January 2007
NCT00041015 Completed Phase 3 Combination Chemotherapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer September 2001 November 2002
NCT00041054 Completed Phase 2 Combination Chemotherapy and Exisulind in Treating Patients With Extensive-Stage Small Cell Lung Cancer June 2002 February 2008
NCT00041327 Completed Phase 2 Combination Chemotherapy Followed By Antiviral Therapy and Interferon Alfa in Treating Patients With HTLV-1-Related Adult T-Cell Leukemia/Lymphoma October 2002 December 2006
NCT03059667 Completed Phase 2 Immunotherapy as Second-line in Patient With Small Cell Lung Cancer March 13, 2017 December 1, 2020
NCT00042978 Completed Phase 2 Carboplatin and Etoposide With or Without Oblimersen Sodium in Treating Patients With Extensive Stage Small Cell Lung Cancer April 2003
NCT00043979 Completed Phase 2 Stem Cell Transplantation in Patients With High-Risk and Recurrent Pediatric Sarcomas September 19, 2002 December 14, 2011
NCT00045162 Completed Phase 3 S0124: Cisplatin Combined With Irinotecan or Etoposide For Extensive-Stage Small Cell Lung Cancer November 2002 December 2009
NCT03036904 Completed Phase 1 Study of Venetoclax Plus DA-EPOCH-R for the Treatment of Aggressive B-Cell Lymphomas February 6, 2017 November 11, 2021
NCT00047281 Completed Phase 2 Thalidomide, Celecoxib, and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Malignant Glioma March 2004 February 2006
NCT00047320 Completed Phase 2 Neoadjuvant Chemotherapy With or Without Second-Look Surgery Followed by Radiation Therapy With or Without Peripheral Stem Cell Transplantation in Treating Patients With Intracranial Germ Cell Tumors January 2004 February 2009
NCT00049036 Completed Phase 2 Combination Chemotherapy and Rituximab in Treating Patients With HIV-Associated Stage I, Stage II, Stage III, or Stage IV Non-Hodgkin's Lymphoma March 2003 May 2009
NCT00049218 Completed Phase 1/Phase 2 Chemotherapy Followed By Vaccine Therapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer April 2003 May 2014
NCT00049439 Completed Phase 2 Combination Chemotherapy in Treating Patients With AIDS-Related Non-Hodgkin's Lymphoma March 1998 February 2008
NCT00049569 Completed N/A Combination Chemotherapy and Imatinib Mesylate in Treating Children With Relapsed Acute Lymphoblastic Leukemia January 2003
NCT00049595 Completed Phase 3 Comparison of Two Combination Chemotherapy Regimens in Treating Patients With Stage III or Stage IV Hodgkin's Lymphoma August 2002
NCT00051311 Completed Phase 2 Modified Stem Cell Transplant Procedure to Treat Patients With Blood and Immune System Cancers January 3, 2003 September 25, 2014
NCT00052299 Completed Phase 3 Chemotherapy With or Without Gemtuzumab Ozogamicin in Treating Older Patients With Acute Myeloid Leukemia September 2002 February 2012
NCT00052923 Completed Phase 3 Stem Cell Transplantation With or Without Rituximab in Treating Patients With Relapsed or Progressive B-Cell Diffuse Large Cell Lymphoma March 2003
NCT00053118 Completed Phase 1 Chemotherapy and Stem Cell Transplantation in Treating Children With Central Nervous System Cancer March 2002 July 2004
NCT00053352 Completed Phase 3 Surgery and Combination Chemotherapy in Treating Children With Extracranial Germ Cell Tumors November 3, 2003 June 30, 2021
NCT00053768 Completed Phase 3 Combination Chemotherapy Followed By Radiation Therapy in Treating Patients With Aggressive Non-Hodgkin's Lymphoma April 2002 December 5, 2006
NCT00054327 Completed Phase 2 Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer November 2000 September 2011
NCT00054665 Completed Phase 2 PS-341 Alone and PS-341 Plus EPOCH Chemotherapy to Treat Non-Hodgkin's Lymphoma February 2003 July 2009
NCT00057811 Completed Phase 2 Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma June 2004 July 2014
NCT00057837 Completed Phase 2 Comparison of Two Combination Chemotherapy Regimens in Treating Patients With Extensive-Stage Small Cell Lung Cancer July 14, 2004 August 2012
NCT00058292 Completed Phase 1 Radiolabeled Monoclonal Antibody Therapy and High-Dose Chemotherapy Followed By Autologous Peripheral Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma April 2000 March 2009
NCT03023046 Completed Phase 2 Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma February 23, 2017 May 1, 2022
NCT00060255 Completed Phase 2 High-Dose Chemotherapy, Total-Body Irradiation, and Autologous Stem Cell Transplantation or Bone Marrow Transplantation in Treating Patients With Hematologic Cancer or Solid Tumors December 1991 February 2013
NCT00061893 Completed Phase 2 Vinblastine, Celecoxib, and Combination Chemotherapy in Treating Patients With Newly-Diagnosed Metastatic Ewing's Sarcoma Family of Tumors April 2004 December 2013
NCT00062439 Completed Phase 2 S0220: Chemoradiotherapy Followed By Surgery and Docetaxel in Treating Patients With Pancoast Tumors July 2003 December 2010
NCT00066222 Completed Phase 2 Cisplatin, Etoposide, and Radiation Therapy in Treating Patients With Limited-Stage Small Cell Lung Cancer June 2003 November 2013
NCT00066482 Completed N/A Combination Chemotherapy in Treating Children With Newly Diagnosed Malignant Germ Cell Tumors July 2004
NCT00066742 Completed Phase 2 Tirapazamine Combined With Chemo and RT in Limited-Stage Small Cell Lung Cancer September 2003 August 2009
NCT00070174 Completed Phase 2 Gemtuzumab Ozogamicin in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia Undergoing Remission Induction and Intensification Therapy December 2003 December 2013
NCT00070187 Completed Phase 2/Phase 3 Immunotherapy Using Cyclosporine, Interferon Gamma, and Interleukin-2 After High-Dose Myeloablative Chemotherapy With Autologous Stem Cell Transplantation in Treating Patients With Refractory or Relapsed Hodgkin's Lymphoma November 2003
NCT00070200 Completed Phase 1 Induction Chemotherapy Using Cyclophosphamide and Topotecan in Treating Patients Who Are Undergoing Autologous Peripheral Stem Cell Transplantation for Newly Diagnosed or Progressive Neuroblastoma March 2004 December 2013
NCT03019640 Completed Phase 2 Umbilical Cord Blood NK Cells, Rituximab, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Patients With Recurrent or Refractory B-Cell Non-Hodgkin's Lymphoma October 10, 2017 August 16, 2021
NCT00072384 Completed Phase 3 Systemic Chemotherapy and Subtenon Carboplatin, and Local Ophthalmic Therapy in Children With Intraocular Retinoblastoma April 16, 2007 June 30, 2021
NCT00072527 Completed Phase 2 Cisplatin and Irinotecan Followed by Carboplatin, Etoposide, and Radiation Therapy in Treating Patients With Limited-Stage Small Cell Lung Cancer November 2003 January 2013
NCT00073918 Completed Phase 2 Iodine I 131 Tositumomab, Etoposide and Cyclophosphamide Followed by Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma February 1999 October 2, 2011
NCT00078988 Completed Phase 3 High-Dose Chemotherapy Plus Autologous Stem Cell Transplantation Compared With Intermediate-Dose Chemotherapy Plus Autologous Stem Cell Transplantation With or Without Isotretinoin in Treating Young Patients With Recurrent High-Grade Gliomas October 2004 September 2006
NCT00079040 Completed Phase 2 Cisplatin, Etoposide, and Bevacizumab in Treating Patients With Previously Untreated Extensive Stage Small Cell Lung Cancer January 2006 January 2009
NCT00079105 Completed Phase 2 A Phase II Study VEPEMB In Patients With Hodgkin's Lymphoma Aged ≥ 60 Years January 2004 December 2010
NCT00080886 Completed Phase 2 Rituximab, Carmustine; Cytarabine, Etoposide, & Melphalan; Stem Cell Transplantation for Non-Hodgkin's Lymphoma May 8, 2002 March 12, 2015
NCT00080925 Completed Phase 1 T-Cell-Depleted Allogeneic Stem Cell Transplantation After Immunoablative Induction Chemotherapy and Reduced-Intensity Transplantation Conditioning in Treating Patients With Hematologic Malignancies February 2004 December 2010
NCT00083161 Completed Phase 2 Cisplatin, Etoposide, and Cyclophosphamide in Treating Patients With Extensive-Stage Small Cell Lung Cancer June 2003 May 2010
NCT00083538 Completed Phase 2 Study of Tumor Antigen-Pulsed Autologous Dendritic Cell Vaccination Administrated Subcutaneously or Intranodally February 2001 December 2007
NCT00083551 Completed Phase 3 UARK 98-026 TT II: Multiple Myeloma Evaluating Anti-Angiogenesis With Thalidomide and Post-Transplant Consolidation Chemotherapy August 1998 August 2014
NCT00083681 Completed Phase 2 DCEP in Combination With Thalidomide as Salvage Therapy for Post Transplantation Relapse June 1998 May 2005
NCT00083915 Completed Phase 3 DTPACE Followed by Tandem Transplant With Melphalan (MEL) 200 Versus MEL/Dexamethasone/Thalidomide (DT) Platinol/Adriamycin/Etoposide (PACE) Hybrid and DTPACE Consolidation June 2001 June 2010
NCT00084838 Completed Phase 2 Chemotherapy Combined With Radiation Therapy for Newly Diagnosed CNS AT/RT February 2003 March 2013
NCT00085098 Completed Phase 3 Radiation Therapy Compared With Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Primary Central Nervous System (CNS) Germ Cell Tumor January 2007 May 2009
NCT00086944 Completed Phase 1/Phase 2 Oblimersen, Rituximab and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma May 2004
NCT00094497 Completed Phase 3 Trial in Locally Advanced and Metastatic Adrenocortical Carcinoma Treatment (FIRM-ACT) June 2004 December 2010
NCT00096135 Completed N/A Combination Chemotherapy and Radiation Therapy in Treating Patients With Acute Lymphoblastic Leukemia That Has Relapsed in the CNS or Testes November 2004
NCT00098774 Completed Phase 2 Rituximab and Combination Chemotherapy in Treating Patients With Newly Diagnosed Primary CNS Lymphoma October 2004 September 2014
NCT00098839 Completed Phase 1/Phase 2 Chemoimmunotherapy With Epratuzumab in Relapsed Acute Lymphoblastic Leukemia (ALL) February 2005 April 2011
NCT00100477 Completed Phase 2 Use of Topotecan in Patients With Refractory Acute Leukemia August 1998 June 2001
NCT00107354 Completed Phase 1 Cellular Adoptive Immunotherapy in Treating Patients With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndromes That Relapsed After Donor Stem Cell Transplant December 1998
NCT00109031 Completed Phase 3 Palifermin for the Reduction of Oral Mucositis in Single-dose Evaluation (PROMISE) January 2005 December 2010
NCT00109928 Completed Phase 2 S0350 Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Peripheral T-Cell Non-Hodgkin's Lymphoma September 2005 April 2014
NCT00112853 Completed Phase 1 Tipifarnib and Etoposide in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia March 2005
NCT00118209 Completed Phase 3 Rituximab and Combination Chemotherapy in Treating Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma May 2005 November 15, 2021
NCT02949895 Completed Phase 1 Study of BMS-986012 in Subjects With Small Cell Lung Caner November 29, 2016 August 29, 2017
NCT00134030 Completed Phase 3 Combination Chemotherapy, PEG-Interferon Alfa-2b, and Surgery in Treating Patients With Osteosarcoma November 14, 2005 September 30, 2022
NCT00137995 Completed Phase 3 R-ICE Versus R-DHAP in Patients Aged 18-65 With Relapse Diffuse Large B-cell Lymphoma June 2003 October 2008
NCT00146120 Completed Phase 3 Risk-Adapted Therapy of Acute Myeloid Leukemia of Adults (18-60 Years) According to the Cytogenetic Result May 1998 May 2005
NCT00151060 Completed Phase 2 Estramustine, Etoposide and Paclitaxel Treatment for Hormonally Responsive Adenocarcinoma of the Prostate December 1998 June 2006
NCT00151242 Completed Phase 2/Phase 3 Study on All-Trans Retinoic Acid, Induction and Consolidation Therapy, and Pegfilgrastim After Consolidation Therapy in Younger Patients With Newly Diagnosed Acute Myeloid Leukemia July 2004 August 2013
NCT00165451 Completed Phase 2 A Trial of Thalidomide, Celecoxib, Etoposide and Cyclophosphamide in Patients With Relapsed or Progressive Cancer June 2001 October 2006
NCT00176605 Completed Phase 2 Phase II Metronomic Dosing, Etoposide, Cyclophosphamide, D0 Prostate Cancer May 2005 October 2008
NCT00187122 Completed N/A Treatment for Patients With Stage III or IV Non-Hodgkin Lymphoma March 1993 June 2004
NCT00191139 Completed Phase 2 Gemcitabine or Gemcitabine Plus Docetaxel After Cisplatin, Etoposide and Radiation in Non Small Cell Lung Cancer (NSCLC) March 2003 February 2009
NCT00193505 Completed Phase 2 Ifosfamide/Carboplatin/Etoposide/Rituxan Followed by Zevalin in Relapsed/Refractory Intermediate Grade B-Cell Lymphoma October 2003 August 2005
NCT00193531 Completed Phase 2 Paclitaxel, Carboplatin, and Oral Etoposide Followed by Weekly Paclitaxel in High Grade Neuroendocrine Carcinoma December 1998 January 2007
NCT00193596 Completed Phase 3 Gemcitabine/Irinotecan/ZD1839 vs Paclitaxel/Carboplatin/Etoposide/ZD1839 in Carcinoma of Unknown Primary Site September 2003 June 2009
NCT00198991 Completed Phase 4 German Multicenter Trial for Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Adults (07/2003) April 2003 June 30, 2013
NCT02867956 Completed Phase 2 Apatinib and Etoposide in Patients With Platinum Resistant or Refractory Ovarian Cancer August 10, 2016 September 10, 2019
NCT00204646 Completed Phase 2 Neoadjuvant Adriamycin and Ifosfamide Plus High-Dose ICE in Patients With Soft Tissue Sarcoma (STS) February 1999 December 2006
NCT02825147 Completed Phase 2 Pegaspargase and Methotrexate Based Regimens for Newly Diagnosed Extranodal NK/T Cell Lymphoma September 2013 July 2017
NCT00216125 Completed Phase 3 Cisplatin/Etoposide/Radiotherapy +/- Consolidation Docetaxel in Advanced Stage III Non-Small Cell Lung Cancer February 2002 March 2008
NCT00217503 Completed Phase 2 Bortezomib and Antiviral Therapy Followed By Effusion Drainage, Bevacizumab, and Combination Chemotherapy in Treating Patients With Primary Effusion Lymphoma July 2005 June 2007
NCT00231582 Completed Phase 2 High-dose Chemotherapy With Autologous Stem Cell Transplantation in Poor Prognosis Germ-cell Tumors: TAXIF II September 2004 January 2010
NCT00233987 Completed Phase 2 S0410 Tandem Stem Cell Transplantation in Treating Patients With Progressive or Recurrent Hodgkin's Lymphoma October 2005 December 2017
NCT00238368 Completed Phase 2 Fludeoxyglucose F 18 Positron Emission Tomography in Predicting Risk of Relapse in Patients With Non-Hodgkin's Lymphoma Who Are Undergoing Combination Chemotherapy With or Without Autologous Stem Cell or Bone Marrow Transplant February 2004 September 17, 2007
NCT00242996 Completed Phase 2 Rituximab, Cyclophosphamide, and G-CSF Followed By Combination Chemotherapy in Treating Patients Who Are Undergoing Autologous Stem Cell Transplant Followed By Rituximab and GM-CSF for Refractory Diffuse Large B-Cell Lymphoma March 2004 April 2007
NCT00244946 Completed Phase 1 Combination Chemotherapy Followed By Autologous Stem Cell Transplant, and White Blood Cell Infusions in Treating Patients With Non-Hodgkin's Lymphoma March 2004 March 2013
NCT00253435 Completed Phase 2 N2001-02: I-MIBG With Intensive Chemotherapy and Autologous Stem Cell Rescue for High-Risk Neuroblastoma September 2005 December 2013
NCT00255723 Completed Phase 2 Combination Chemotherapy and Radiation Therapy in Treating Patients Who Are Undergoing an Autologous Stem Cell Transplant for Relapsed or Refractory Hodgkin's Lymphoma April 2004 July 2012
NCT00264953 Completed Phase 3 HD11 for Intermediate Stages May 1998
NCT00265031 Completed Phase 3 HD12 for Advanced Stages January 1999
NCT00265889 Completed Phase 2 Autologous Stem Cell Transplant in Treating Patients With Progressive or Recurrent Hodgkin's Lymphoma February 2002 April 2010
NCT00274807 Completed Phase 2 Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia June 2001 May 2008
NCT00274924 Completed Phase 2 Rituximab and Combination Chemotherapy in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Non-Hodgkin's Lymphoma September 26, 2006 March 2019
NCT02786719 Completed N/A High-Risk Neuroblastoma Chemotherapy Without G-CSF June 2016 February 5, 2019
NCT00275015 Completed Phase 2 Cyclophosphamide and Total Body Irradiation in Treating Patients Who Are Undergoing an Autologous Peripheral Stem Cell Transplant For Chronic Lymphocytic Leukemia January 1998 April 2012
NCT02763579 Completed Phase 3 A Study of Carboplatin Plus Etoposide With or Without Atezolizumab in Participants With Untreated Extensive-Stage (ES) Small Cell Lung Cancer (SCLC) June 7, 2016 July 7, 2022
NCT02686346 Completed Phase 1/Phase 2 Brentuximab Vedotin in Refractory/Relapsed Hodgkin Lymphoma Treated by ICE March 2016 July 12, 2021
NCT00276809 Completed Phase 2 Combination Chemotherapy, Total-Body Irradiation, and Alemtuzumab in Treating Patients Undergoing an Autologous Stem Cell Transplant for Stage I, Stage II, Stage III, or Stage IV Chronic Lymphocytic Leukemia June 2001 September 2004
NCT02636322 Completed Phase 2 Smart Start: A Phase II Study of Rituximab, Lenalidomide, and Ibrutinib March 29, 2016 October 24, 2022
NCT00303849 Completed Phase 1/Phase 2 Carboplatin, Melphalan, Etoposide Phosphate, Mannitol, and Sodium Thiosulfate in Treating Patients With Previously Treated Brain Tumors September 15, 2005 March 12, 2021
NCT00304018 Completed Phase 1 Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematologic Cancer October 2002 March 2009
NCT00304070 Completed Phase 3 Cisplatin-Based Chemotherapy and/or Surgery in Treating Young Patients With Adrenocortical Tumor May 3, 2007 June 30, 2023
NCT00304083 Completed Phase 2 Combination Chemotherapy in Treating Patients With Stage III or Stage IV Malignant Peripheral Nerve Sheath Tumors December 2005 June 2014
NCT02626338 Completed Phase 1/Phase 2 Pilot Study of Crenolanib Combined With Standard Salvage Chemotherapy in Subjects With R/R AML February 2016 February 2018
NCT00315705 Completed Phase 1/Phase 2 A Study of Clofarabine in Combination With Etoposide and Cyclophosphamide in Children With Acute Leukemias. March 2006 May 2010
NCT00324298 Completed Phase 3 Bleomycin, Etoposide, and Cisplatin in Treating Patients With Metastatic Germ Cell Cancer of the Testicles July 2003 March 2011
NCT02583893 Completed Phase 2 Biomarkers in Predicting Treatment Response to Sirolimus and Chemotherapy in Patients With High-Risk Acute Myeloid Leukemia October 7, 2015 May 17, 2023
NCT02561273 Completed Phase 1/Phase 2 Combination Chemotherapy & Lenalidomide in Newly Diagnosed Stage II-IV Peripheral T-cell Non-Hodgkin's Lymphoma September 28, 2015 November 1, 2020
NCT00335556 Completed Phase 2 Combination Chemotherapy, Radiation Therapy, and/or Surgery in Treating Patients With High-Risk Kidney Tumors June 2006
NCT00335738 Completed Phase 3 Vincristine, Carboplatin, and Etoposide or Observation Only in Treating Patients Who Have Undergone Surgery for Newly Diagnosed Retinoblastoma December 2005 September 30, 2020
NCT00345865 Completed Phase 2 Autologous Peripheral Stem Cell Transplant in Treating Patients With Non-Hodgkin's Lymphoma or Hodgkin's Lymphoma August 24, 2005 June 28, 2019
NCT00349778 Completed Phase 2 High-Dose Sequential Therapy and Single Autologous Transplantation for Multiple Myeloma August 2006 April 2010
NCT00352027 Completed Phase 2 Chemotherapy With Low-Dose Radiation for Pediatric Hodgkin Lymphoma July 20, 2006 November 15, 2022
NCT02523976 Completed Phase 2 Dasatinib Combined With Chemotherapy in Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia August 1, 2015 December 31, 2021
NCT00354744 Completed Phase 3 High-Dose Combination Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Metastatic Rhabdomyosarcoma or Ectomesenchymoma July 2006 June 30, 2019
NCT00357305 Completed Phase 1 Vorinostat, Cytarabine, and Etoposide in Treating Patients With Relapsed and/or Refractory Acute Leukemia or Myelodysplastic Syndromes or Myeloproliferative Disorders May 2006
NCT00357500 Completed Phase 2 Etoposide, Cyclophosphamide, Thalidomide, Celecoxib, and Fenofibrate in Relapsed or Progressive Cancer January 2005 December 2013
NCT00363415 Completed Phase 3 Study of Pemetrexed and Carboplatin Compared With Etoposide Carboplatin to Treat Extensive-Stage Small Cell Lung Cancer August 2006 June 2008
NCT00365755 Completed Phase 3 Combination Chemotherapy in Treating Young Patients Who Are Undergoing Surgery and an Autologous Bone Marrow Transplant for Disseminated Neuroblastoma March 2008
NCT00369317 Completed Phase 3 Combination Chemotherapy in Treating Young Patients With Down Syndrome and Acute Myeloid Leukemia or Myelodysplastic Syndromes March 2007 December 31, 2021
NCT00372593 Completed Phase 3 Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia August 2006 September 30, 2020
NCT02512926 Completed Phase 1 Carfilzomib in Combination With Cyclophosphamide and Etoposide for Children February 16, 2016 November 7, 2023
NCT00381680 Completed Phase 3 Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia March 2007
NCT00387699 Completed Phase 2 Bevacizumab, Cisplatin, Etoposide, and Radiation Therapy in Treating Patients With Limited-Stage Small Cell Lung Cancer October 2006 April 2014
NCT00388349 Completed Phase 2 Gemcitabine and Hodgkin's Disease Chemotherapy Followed by Peripheral Blood Stem Cell Rescue for Hodgkin's Disease September 2001 September 2010
NCT00388960 Completed Phase 2 Study of Amrubicin With or Without Cisplatin Versus Etoposide-cisplatin for Extensive Stage Small Cell Lung Cancer November 1, 2006 December 1, 2010
NCT00392834 Completed Phase 2 Rituximab and Combination Chemotherapy in Treating Patients With Newly Diagnosed, HIV-Associated Burkitt's Lymphoma September 2006 July 2013
NCT02504359 Completed Phase 1 Combination Chemotherapy and Donor Stem Cell Transplant Followed by Ixazomib Citrate Maintenance Therapy in Treating Patients With Relapsed High-Risk Multiple Myeloma July 20, 2015 September 9, 2020
NCT00398554 Completed Phase 2 Combination Chemotherapy in Treating Young Male Patients With Hodgkin's Lymphoma June 2005 March 2013
NCT00400946 Completed Phase 3 Treatment of Acute Lymphoblastic Leukemia in Children April 2005 June 2019
NCT00401609 Completed Phase 1/Phase 2 G-Step: Gemcitabine Based Small-cell Lung Cancer Treatment in Elderly Patients November 2000 February 2009
NCT00416598 Completed Phase 2 Decitabine as Maintenance Therapy After Standard Therapy in Treating Patients With Previously Untreated Acute Myeloid Leukemia November 15, 2006 December 1, 2016
NCT02502708 Completed Phase 1 Study of the IDO Pathway Inhibitor, Indoximod, and Temozolomide for Pediatric Patients With Progressive Primary Malignant Brain Tumors October 2015 February 28, 2020
NCT00416832 Completed Phase 2 Combination Chemotherapy and Radiation Therapy in Treating Young Patients With Hodgkin's Lymphoma November 2002 December 2005
NCT02499770 Completed Phase 1/Phase 2 Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Etoposide and Carboplatin in Extensive Stage Small Cell Lung Cancer (SCLC) June 26, 2015 February 22, 2019
NCT00426101 Completed Phase 3 Treatment Protocol for Hemophagocytic Lymphohistiocytosis 2004 January 2004 December 2017
NCT00427791 Completed Phase 2 Rituximab to the Preparative Regimen of Etoposide and Total Body Irradiation in Acute Lymphoblastic Leukemia July 2005 October 2009
NCT00430118 Completed Phase 3 Combination Chemotherapy Based on Risk of Relapse in Treating Young Patients With Acute Lymphoblastic Leukemia July 2000 January 2012
NCT00432094 Completed Phase 2 Autologous Peripheral Blood Stem Cell Transplant for Germ Cell Tumors December 19, 2006 March 2021
NCT00439361 Completed Phase 1 Velcade Plus ICE for Patients With Relapsed Classical Hodgkin Lymphoma February 2007 June 2012
NCT00439556 Completed Phase 2 Bortezomib and Chemotherapy in Treating Participants With Lymphoid Malignancies Undergoing Stem Cell Transplant February 13, 2007 June 7, 2018
NCT00450801 Completed Phase 2 R-MACLO-IVAM and Thalidomide in Untreated Mantle Cell Lymphoma April 2004 July 2015
NCT00453154 Completed Phase 1/Phase 2 Cisplatin or Carboplatin, and Etoposide With or Without Sunitinib Malate in Treating Patients With Extensive-Stage Small Cell Lung Cancer March 15, 2007 August 20, 2015
NCT00453232 Completed Phase 2 Combination Chemotherapy and Pegfilgrastim in Treating Men With Metastatic Germ Cell Tumors August 2004 January 2009
NCT00458848 Completed Phase 2 Chemotherapy With or Without Imatinib and/or Peripheral Stem Cell Transplant in Acute Lymphoblastic Leukemia October 2004 March 2014
NCT00472056 Completed Phase 2 Rituximab in Addition to Autologous Transplantation With BEAM for Patients With Lymphoid Malignancies March 2005 June 2012
NCT00477035 Completed Phase 1 Post-transplant Autologous Cytokine-induced Killer (CIK) Cells for Treatment of High Risk Hematologic Malignancies May 2006 March 2011
NCT02489903 Completed Phase 2 RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT) June 2015 December 6, 2021
NCT00499343 Completed Phase 2 G-CSF Versus G-CSF Plus GM-CSF for Stem Cell Mobilization in NHL Patients January 2004 October 2008
NCT00499616 Completed Phase 3 Combination Chemotherapy and Surgery With or Without Isotretinoin in Treating Young Patients With Neuroblastoma October 8, 2007 June 30, 2021
NCT02471911 Completed Phase 1 KPT-330 Plus RICE for Relapsed/Refractory Aggressive B-Cell Lymphoma December 11, 2015 October 14, 2021
NCT00504140 Completed Phase 2 Recombinant Interferon Alpha and Etoposide in Relapsed Osteosarcoma November 1996 March 2009
NCT00512252 Completed Phase 1/Phase 2 AMD3100 Plus Mitoxantrone, Etoposide and Cytarabine in Acute Myeloid Leukemia July 2007 June 2010
NCT00513162 Completed Phase 1 Valproate and Etoposide for Patients With Neuronal Tumors and Brain Metastases July 2007
NCT00513474 Completed Phase 1 Rasburicase in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer or Other Disease Undergoing Donor Stem Cell Transplant January 2008 February 12, 2013
NCT00514540 Completed Phase 2 Carboplatin Plus Docetaxel (Taxotere) in Anaplastic Prostate Cancer May 2006 April 2013
NCT00521014 Completed Phase 2 GM-CSF and Rituximab After Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Follicular Non-Hodgkin Lymphoma October 2007 July 2013
NCT02432274 Completed Phase 1/Phase 2 Study of Lenvatinib in Children and Adolescents With Refractory or Relapsed Solid Malignancies and Young Adults With Osteosarcoma December 29, 2014 July 20, 2022
NCT00536601 Completed N/A High-Dose Chemotherapy With or Without Total-Body Irradiation Followed by Autologous Stem Cell Transplant in Treating Patients With Hematologic Cancer or Solid Tumors June 29, 2006 July 9, 2018
NCT00536978 Completed Phase 2 Natural Killer (NK) Cell Adback After Allogeneic Stem Cell Transplant With Campath-IH Plus Chemorx for Patients With Lymphoid Malignancies September 2007 November 2010
NCT02400281 Completed Phase 1/Phase 2 Study of Crenolanib Combined With Chemotherapy in FLT3-mutated Acute Myeloid Leukemia Patients September 2015 July 15, 2020
NCT02385110 Completed Phase 2 Alemtuzumab or Tocilizumab in Combination With Etoposide and Dexamethasone for the Treatment of Adult Patients With Hemophagocytic Lymphohistiocytosis September 23, 2015 January 24, 2023
NCT00544570 Completed N/A High-Dose Chemotherapy in Treating Patients Undergoing Stem Cell Transplant for Recurrent or Refractory Hodgkin's Lymphoma April 1998 December 2007
NCT00544596 Completed Phase 1 R-(-)-Gossypol Acetic Acid, Cisplatin, and Etoposide in Treating Patients With Advanced Solid Tumors or Extensive Stage Small Cell Lung Cancer September 2007
NCT02348216 Completed Phase 1/Phase 2 Study Evaluating the Safety and Efficacy of KTE-C19 in Adult Participants With Refractory Aggressive Non-Hodgkin Lymphoma April 21, 2015 July 27, 2023
NCT00551005 Completed Phase 1 Etoposide and Celecoxib in Patients With Advanced Cancer December 2001 February 2012
NCT00554463 Completed Phase 2 G-CSF and Pegfilgrastim in Treating Neutropenia in Patients Undergoing Radiation Therapy and Chemotherapy for Limited Stage Small Cell Lung Cancer January 2008 August 3, 2011
NCT00556127 Completed Phase 2 Rituximab in Addition to Chemotherapy With Autologous Stem Cell Transplantation as Treatment Diffuse Large B-Cell Lymphoma June 2002 September 2006
NCT00559104 Completed Phase 2 Combination Chemotherapy With or Without Total-Body Irradiation Followed By Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma October 1998 July 2011
NCT00562978 Completed Phase 1/Phase 2 Yttrium Y 90 Ibritumomab Tiuxetan, Etoposide, Cyclophosphamide, and an AHSCT in Non-Hodgkin's Lymphoma Patients May 16, 2000 May 21, 2018
NCT00567567 Completed Phase 3 Comparing Two Different Myeloablation Therapies in Treating Young Patients Who Are Undergoing a Stem Cell Transplant for High-Risk Neuroblastoma November 5, 2007 March 31, 2022
NCT00569985 Completed Phase 1 Gene Therapy-Treated Stem Cells in Treating Patients Undergoing Stem Cell Transplant for Intermediate-Grade or High-Grade AIDS-Related Lymphoma June 2007 November 12, 2019
NCT00573690 Completed Phase 1 Sorafenib Combined With Cisplatin and Etoposide or Carboplatin and Pemetrexed in Treating Patients With Metastatic Solid Tumors September 2007 February 2011
NCT00577629 Completed Phase 2 Chemotherapy With Monoclonal Antibody and Radioimmunotherapy for High-Risk B-Cell Non-Hodgkins Lymphoma June 18, 2005 November 3, 2016
NCT00577993 Completed Phase 3 Fludarabine, Mitoxantrone, and Dexamethasone (FND) Plus Rituximab for Lymphoma Patients March 16, 1998 August 24, 2017
NCT00589056 Completed Phase 1/Phase 2 Nelfinavir, Radiation Therapy, Cisplatin, and Etoposide in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery June 2007 March 2012
NCT00589563 Completed Phase 2 Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant For Hematological Cancer May 2007 February 2012
NCT00591630 Completed Phase 2 Zevalin/BEAM/Rituximab vs BEAM/Rituximab With or Without Rituximab in Autologous Stem Cell Transplantation November 14, 2007 March 5, 2020
NCT00598169 Completed Phase 1 Bortezomib, Ifosfamide, Carboplatin, and Etoposide, With or Without Rituximab, in Treating Patients With Relapsed or Refractory AIDS-Related Non-Hodgkin Lymphoma November 2007 November 2014
NCT00601718 Completed Phase 1/Phase 2 Vorinostat, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Lymphoma or Previously Untreated T-Cell Non-Hodgkin Lymphoma or Mantle Cell Lymphoma December 2007
NCT00602771 Completed Phase 2 Tipifarnib and Etoposide in Treating Older Patients With Newly Diagnosed, Previously Untreated Acute Myeloid Leukemia January 2008 October 2011
NCT00613457 Completed Phase 3 Combination Chemotherapy Based on Risk of Relapse in Treating Young Patients With Acute Lymphoblastic Leukemia September 2000 July 2006
NCT00613626 Completed Phase 2 Cisplatin + Etoposide +/- Concurrent ZD6474 in Previously Untreated Extensive Stage Small Cell Lung Cancer January 2008 August 2015
NCT00618501 Completed Phase 2 Imatinib Mesylate and Combination Chemotherapy With or Without a Donor Stem Cell Transplant in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia October 2005 January 2009
NCT00618813 Completed N/A Two Regimens of Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed Localized Ewing Sarcoma Family of Tumors March 2008
NCT00621361 Completed Phase 1 Phase I Safety and Tolerability Study of Cediranib (RECENTIN™, AZD2171) in Combination With Chemo in First Line Lung Cancer Patients February 2008 February 2012
NCT00627354 Completed Phase 2 Mitoxantrone, Etoposide, and Vinorelbine As Second-Line Therapy in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy September 2006
NCT00634244 Completed Phase 2 Comparing Three Different Combination Chemotherapy Regimens in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia October 2008 October 2014
NCT00653068 Completed Phase 3 Combination Chemotherapy, Radiation Therapy, and an Autologous Peripheral Blood Stem Cell Transplant in Treating Young Patients With Atypical Teratoid/Rhabdoid Tumor of the Central Nervous System February 10, 2009 March 31, 2024
NCT02306291 Completed Phase 1/Phase 2 Study to Determine Safety, Pharmacokinetics and Efficacy of GMI-1271 in Combination With Chemotherapy in AML March 2015 May 2018
NCT00662233 Completed Early Phase 1 Combination Chemotherapy in Treating Patients With Sarcoma October 1991 October 21, 2013
NCT00666484 Completed Phase 2 Combination Chemotherapy in Treating Younger Patients With Hodgkin Lymphoma March 2008 September 2012
NCT00666588 Completed Phase 2 Bortezomib and Combination Chemotherapy in Treating Younger Patients With Recurrent, Refractory, or Secondary Acute Myeloid Leukemia April 2008 December 2012
NCT00667342 Completed Phase 2 A Study of Bevacizumab in Combination With Chemotherapy for Treatment of Osteosarcoma June 3, 2008 August 2017
NCT00678327 Completed Phase 3 Fludeoxyglucose F 18-PET/CT Imaging in Assessing Response to Chemotherapy in Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Hodgkin Lymphoma August 29, 2008 May 1, 2024
NCT00686959 Completed Phase 3 Chemotherapy and Radiation in Treating Participants With Stage 3 Non-Small Cell Lung Cancer September 2008 November 2014
NCT00691015 Completed Phase 2 Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant May 2008 April 2014
NCT00691210 Completed Phase 1 Phase I Vorinostat in Combination With Niacinamide and Etoposide for Lymphoid Malignancies June 2008 March 2015
NCT00693719 Completed Phase 2 Irinotecan and Etoposide in Treating Patients With Recurrent, Locally Advanced, or Metastatic Breast Cancer August 2007 May 2013
NCT00695409 Completed Phase 2 Yttrium-90 Ibritumomab Tiuxetan Plus High-Dose BEAM Followed By ASCT For Relapsed B-Cell Non-Hodgkin Lymphoma March 18, 2008 March 27, 2017
NCT00697671 Completed Phase 1 Pilot Study of Haploidentical Natural Killer Cell Infusions for Poor Prognosis Non-AML Hematologic Malignancies March 2007 May 2013
NCT00703820 Completed Phase 3 Clofarabine Plus Cytarabine Versus Conventional Induction Therapy And A Study Of NK Cell Transplantation In Newly Diagnosed Acute Myeloid Leukemia August 4, 2008 August 14, 2020
NCT00720109 Completed Phase 2/Phase 3 Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia July 14, 2008 March 31, 2020
NCT02299518 Completed Phase 1 Selinexor and Chemotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia May 18, 2015 March 6, 2018
NCT02298283 Completed Phase 2 Brentuximab Vedotin as Consolidation Treatment in Patients With Stage I/II HL and PET Positivity After 2 Cycles of ABVD April 2015 July 9, 2020
NCT02289690 Completed Phase 1/Phase 2 Dose Escalation and Double-blind Study of Veliparib in Combination With Carboplatin and Etoposide in Treatment-naive Extensive Stage Disease Small Cell Lung Cancer October 13, 2014 April 17, 2019
NCT00732498 Completed Phase 2 Rituximab, Yttrium Y 90 Ibritumomab Tiuxetan in Patients W/Relapsed Stage II, III, or IV Follicular NHL May 15, 2006 October 15, 2018
NCT00742924 Completed Phase 1 Zoledronic Acid and Combination Chemotherapy in Treating Patients With Newly Diagnosed Metastatic Osteosarcoma August 2008
NCT00749723 Completed Phase 2/Phase 3 Therapy Optimization Trial for the Treatment of Relapsed or Refractory Brain Tumors in Children February 1, 2006 January 31, 2016
NCT00774046 Completed Phase 2 High-dose Cytarabine/Mitoxantrone Followed by Autotransplantation for t-MDS/t-AML December 2002 March 2011
NCT00776698 Completed Phase 1 A Study of Avastin (Bevacizumab) in Combination With Thoracic Radiation and Chemotherapy in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer. April 2009 February 2010
NCT00791154 Completed Phase 1/Phase 2 QUILT-2.013: A Trial of AMG 479 or AMG 102 in Combination With Platinum-based Chemotherapy as First-Line Treatment for Extensive Stage Small Cell Lung Cancer December 2008 February 2013
NCT00793845 Completed Phase 2 Tandem High-dose Chemotherapy and Autologous Stem Cell Rescue in Patients With High-risk Neuroblastoma August 2008 January 2018
NCT02243436 Completed Phase 1/Phase 2 Brentuximab Vedotin in Pre-transplant Induction and Consolidation for Relapsed or Refractory Hodgkin Lymphoma November 11, 2014 January 14, 2019
NCT02219737 Completed Phase 1 Ibrutinib and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma September 12, 2014 May 11, 2017
NCT02199184 Completed Phase 2 Dose Adjusted EPOCH Regimen in Combination With Ofatumumab or Rituximab in Treating Patients With Newly Diagnosed or Relapsed or Refractory Burkitt Lymphoma or Relapsed or Refractory Acute Lymphoblastic Leukemia January 14, 2015 February 17, 2023
NCT00822120 Completed Phase 2 S0816 Fludeoxyglucose F 18-PET/CT Imaging and Combination Chemotherapy With or Without Additional Chemotherapy and G-CSF in Treating Patients With Stage III or Stage IV Hodgkin Lymphoma July 2009 June 30, 2022
NCT00826644 Completed Phase 3 Trial of Belotecan/Cisplatin in Chemotherapy Naive Small Cell Lung Cancer Patient January 2009 February 2013
NCT02194049 Completed Phase 1 Cisplatin, Etoposide and PI3K Inhibitor BKM120 in Treating Patients With Advanced Solid Tumors or Small Cell Lung Cancer July 2014 June 2016
NCT00864318 Completed Phase 2 Dose Intensification Study in Refractory Germ Cell Tumors With Relapse and Bad Prognosis March 13, 2009 October 5, 2020
NCT00869752 Completed Phase 1/Phase 2 MK-0646, Etoposide, and Cisplatin in Treating Patients With Extensive-Stage Small Cell Lung Cancer December 16, 2009 July 4, 2012
NCT00887159 Completed Phase 2 A Randomized Phase II Study of Cisplatin and Etoposide in Combination With Either Hedgehog Inhibitor GDC-0449 or IGF-1R MOAB IMC-A12 for Patients With Extensive Stage July 16, 2009 November 15, 2016
NCT00906945 Completed Phase 1/Phase 2 Chemosensitization With Plerixafor Plus G-CSF in Acute Myeloid Leukemia February 2011 September 2015
NCT02161692 Completed Phase 2 Conventional Dose Versus High Dose Sequential Chemotherapy for Poor Prognosis Germ Cell Tumors December 1996 April 2009
NCT02157792 Completed Phase 1 M6620 First in Human Study December 10, 2012 March 11, 2020
NCT00926640 Completed Phase 1 A Phase I Study of Belinostat in Combination With Cisplatin and Etoposide in Adults With Small Cell Lung Carcinoma and Other Advanced Cancers July 1, 2009 April 20, 2018
NCT00927875 Completed Phase 1 A Study of BMS-833923 With Carboplatin and Etoposide Followed by BMS-833923 Alone in Subjects With Extensive-Stage Small Cell Lung Cancer February 2010 September 2012
NCT00936936 Completed Phase 2 High-dose Chemotherapy for Poor-Prognosis Relapsed Germ-Cell Tumors June 2, 2009 January 11, 2024
NCT02130869 Completed Phase 1 A Pilot Study of Immunotherapy Including Haploidentical NK Cell Infusion Following CD133+ Positively-Selected Autologous Hematopoietic Stem Cells in Children With High Risk Solid Tumors or Lymphomas October 10, 2014 December 20, 2017
NCT00967369 Completed Phase 2 Combination Chemotherapy With or Without Bortezomib in Treating Patients With Classical Hodgkin Lymphoma That Has Returned or Does Not Respond to Prior Treatment. August 24, 2009 May 2, 2018
NCT00968760 Completed Phase 1 CD19-specific T Cell Infusion in Patients With B-Lineage Lymphoid Malignancies June 20, 2011 April 23, 2020
NCT00973882 Completed Phase 2 Carboplatin-Etoposide Combination in Hormone-Resistant Prostate Cancers April 2005 January 2010
NCT02070458 Completed Phase 1 Ixazomib, Mitoxantrone Hydrochloride, Etoposide, and Intermediate-Dose Cytarabine in Relapsed or Refractory Acute Myeloid Leukemia October 8, 2014 August 15, 2017
NCT02059239 Completed Phase 1/Phase 2 Bendamustine Bridge to Autologous or Allogeneic Transplant for Relapsed/Refractory Lymphoma June 4, 2014 June 15, 2020
NCT00984997 Completed Phase 2 Combined Modality Treatment for Resectable Non-Small Cell Superior Sulcus Tumors October 1993 June 2015
NCT00992446 Completed Phase 2 Bortezomib and Vorinostat as Maintenance Therapy After Autologous Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma September 2, 2010 October 29, 2019
NCT01000285 Completed Phase 1/Phase 2 EPOCH Chemotherapy and Bortezomib for Associated T-Cell Leukemia Lymphoma September 2010 April 2016
NCT01008462 Completed Phase 2 Autologous Peripheral Blood Stem Cell Transplant Followed by Donor Bone Marrow Transplant in Treating Patients With High-Risk Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia March 18, 2010 June 30, 2018
NCT01013779 Completed Phase 2 Merkel Positron Emission Tomography (PET) Protocol December 2009 June 2021
NCT02029950 Completed Phase 1 Pomalidomide After Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome December 16, 2013 May 13, 2020
NCT02018861 Completed Phase 1/Phase 2 A Phase 1/2, Open-Label, Dose Escalation, Safety and Tolerability Study of INCB050465 and Itacitinib in Subjects With Previously Treated B-Cell Malignancies (CITADEL-101) September 22, 2016 April 12, 2021
NCT02017964 Completed Phase 2 Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed, Non-metastatic Desmoplastic Medulloblastoma December 24, 2013 December 31, 2022
NCT01035463 Completed Phase 1/Phase 2 Lenalidomide Therapy After Chemotherapy & Stem Cell Transplant in Treating Chemotherapy Resistan Non-Hodgkin Lymphoma November 12, 2009 July 27, 2018
NCT01055314 Completed Phase 2 Temozolomide, Cixutumumab, and Combination Chemotherapy in Treating Patients With Metastatic Rhabdomyosarcoma January 2010 June 2016
NCT01059071 Completed Phase 1 Safety Study for Refractory or Relapsed Neuroblastoma With DFMO Alone and in Combination With Etoposide February 2010 May 2015
NCT01076231 Completed Phase 1/Phase 2 Proton Beam Radiation Therapy and Chemotherapy in Treating Patients With Stage III Non-Small Cell Lung Cancer That Can Be Removed By Surgery January 2010 May 24, 2018
NCT01084759 Completed N/A A Pilot Study of Parenteral Testosterone and Oral Etoposide as Therapy for Men With Castration Resistant Prostate Cancer March 2010 October 2014
NCT01097057 Completed Phase 2 Rituximab, Combination Chemotherapy, Filgrastim (G-CSF), and Plerixafor in Treating Patients With Non-Hodgkin Lymphoma Undergoing Mobilization of Autologous Peripheral Blood Stem Cells November 9, 2010 December 26, 2017
NCT01104025 Completed Phase 2 Hybrid Immunotherapy for Hemophagocytic LymphoHistiocytosis April 2010 April 2016
NCT01110135 Completed Phase 2 Bendamustine Hydrochloride, Etoposide, Dexamethasone, and Filgrastim For Peripheral Blood Stem Cell Mobilization in Treating Patients With Refractory or Recurrent Lymphoma or Multiple Myeloma August 2010
NCT01117441 Completed Phase 3 International Collaborative Treatment Protocol For Children And Adolescents With Acute Lymphoblastic Leukemia June 2010 December 31, 2021
NCT01127009 Completed Phase 1 Bortezomib, Mitoxantrone, Etoposide, and Cytarabine in Relapsed or Refractory Acute Myeloid Leukemia July 2010 May 2014
NCT01134861 Completed Phase 3 Radiation Therapy Plus Chemotherapy in Treating Patients With Non-small Cell Lung Cancer July 1994 March 2012
NCT01141712 Completed Phase 2 Autologous Transplant in HIV Patients (BMT CTN 0803) April 2010 June 2016
NCT01154439 Completed Phase 1 Everolimus MICE-regimen in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia October 2010 September 15, 2015
NCT01165112 Completed Phase 1/Phase 2 Bendamustine Hydrochloride, Rituximab, Etoposide, and Carboplatin in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma or Hodgkin Lymphoma September 2010 June 2015
NCT01169636 Completed Phase 1/Phase 2 Panobinostat Plus Ifosfamide, Carboplatin, and Etoposide (ICE) Compared With ICE For Relapsed Hodgkin Lymphoma January 31, 2011 May 17, 2017
NCT01174888 Completed Phase 1 Phase I Combination of Midostaurin, Bortezomib, and Chemo in Relapsed/Refractory Acute Myeloid Leukemia August 2010 May 2016
NCT01180322 Completed Phase 2 Trial Evaluating Induction Therapy With Idarubicin and Etoposide Plus Sequential or Concurrent Azacitidine and Maintenance Therapy With Azacitidine November 2010 October 2, 2016
NCT01184898 Completed N/A Pilot Trial of Sirolimus/MEC in High Risk Acute Myelogenous Leukemia (AML) July 2010 February 2016
NCT01193842 Completed Phase 1/Phase 2 Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas October 6, 2010 May 19, 2022
NCT01197560 Completed Phase 2/Phase 3 Study of Lenalidomide to Evaluate Safety and Effectiveness in Patients With Diffuse Large B-Cell Lymphoma (DLBCL) September 2, 2010 April 5, 2018
NCT01987232 Completed Phase 1/Phase 2 Phase 1b/2 Study of Carfilzomib, Carboplatin, and Etoposide in Patients With Previously Untreated Extensive Stage Small-cell Lung Cancer November 5, 2013 May 4, 2017
NCT01979536 Completed Phase 2 Brentuximab Vedotin or Crizotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II-IV Anaplastic Large Cell Lymphoma November 13, 2013 March 31, 2024
NCT01237808 Completed Phase 3 Study of Low-Dose Cytarabine and Etoposide With or Without All-Trans Retinoic Acid in Older Patients Not Eligible for Intensive Chemotherapy With Acute Myeloid Leukemia and NPM1 Mutation March 2011 July 13, 2018
NCT01251107 Completed Phase 3 Study Comparing ABVD vs BEACOPP in Advanced Hodgkin's Lymphoma March 2000 November 2009
NCT01959477 Completed Early Phase 1 Dose Monitoring of Busulfan and Combination Chemotherapy in Hodgkin or Non-Hodgkin Lymphoma Undergoing Stem Cell Transplant March 2014 April 2015
NCT01329900 Completed Phase 2 Chemotherapy Plus Ofatumumab Followed by G-CSF for Mobilization of Peripheral Blood Stem Cells in Patients With Non-Hodgkin's Lymphomas August 22, 2011 July 21, 2019
NCT01331590 Completed Early Phase 1 Disrupting the Bone Marrow Microenvironment With G-CSF in Acute Lymphoblastic Leukemia July 2011 November 2015
NCT01336933 Completed Phase 2 Combination Chemotherapy and Pralatrexate as First-Line Therapy in Treating Patients With Non-Hodgkin Lymphoma July 6, 2011 December 28, 2016
NCT01958372 Completed Phase 1 Radiation Therapy, Chemotherapy, and Soy Isoflavones in Treating Patients With Stage IIIA-IIIB Non-Small Cell Lung Cancer August 2014 November 11, 2019
NCT01352117 Completed Phase 3 Antiretroviral Therapy (ART) Alone or With Delayed Chemo Versus ART With Immediate Chemo for Limited AIDS-related Kaposi's Sarcoma November 18, 2011 November 29, 2018
NCT01921387 Completed Phase 1/Phase 2 Radiolabeled Monoclonal Antibody and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With High-Risk Lymphoid Malignancies October 9, 2013 July 26, 2020
NCT01900509 Completed Phase 1 Bendamustine Hydrochloride, Clofarabine, and Etoposide in Treating Younger Patients With Relapsed or Refractory Hematologic Malignancies August 2013 May 2016
NCT01411267 Completed Phase 1 AC220 for Children With Relapsed/Refractory ALL or AML September 1, 2011 September 12, 2013
NCT01439568 Completed Phase 2 A Study of LY2510924 in Participants With Extensive-Stage Small Cell Lung Carcinoma September 2011 August 2016
NCT01445535 Completed Phase 1 Phase 1 Trial of Siplizumab and Dose-Adjusted EPOCH-Rituximab in T- and NK-Cell Lymphomas January 13, 2009 October 22, 2020
NCT01450761 Completed Phase 3 Trial in Extensive-Disease Small Cell Lung Cancer (ED-SCLC) Subjects Comparing Ipilimumab Plus Etoposide and Platinum Therapy to Etoposide and Platinum Therapy Alone December 13, 2011 May 17, 2017
NCT01451515 Completed Phase 2 NHL16: Study For Newly Diagnosed Patients With Acute Lymphoblastic Lymphoma May 25, 2012 May 31, 2022
NCT01458366 Completed Phase 1/Phase 2 Phase I/II Study of Bendamustine in Combination With Ofatumumab, Carboplatin and Etoposide November 9, 2011 July 23, 2020
NCT01481272 Completed Phase 2 Ofatumumab With IVAC Salvage Chemotherapy in Diffuse Large B Cell Lymphoma Patients November 2011 December 2018
NCT01505569 Completed N/A Auto Transplant for High Risk or Relapsed Solid or CNS Tumors October 20, 2011 February 1, 2024
NCT01526603 Completed N/A High Dose Chemotherapy and Autologous Transplant for Neuroblastoma March 28, 2012 May 30, 2023
NCT01849783 Completed Phase 2 Autologous Stem Cell Transplant Followed By Maintenance Therapy in Treating Elderly Patients With Multiple Myeloma April 4, 2013 September 30, 2020
NCT01555541 Completed Phase 2 Intensive Consolidation and Stem Cell Mobilization Therapy Followed by Autologous Stem Cell Transplantation in High-risk Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma May 25, 2012 July 1, 2021
NCT01830777 Completed Phase 1 Brentuximab Vedotin + Re-induction Chemotherapy for AML May 2013 May 2019
NCT01569204 Completed Phase 2 Targeted BEACOPP Variants in Patients With Newly Diagnosed Advanced Classical Hodgkin Lymphoma October 2012 December 2017
NCT01589159 Completed Phase 2 A Phase Ⅱ Study of an All-Oral Combination of Low-dose Etoposide/Capecitabine in Patients With Metastatic Breast Cancer Previously Treated With Anthracyclines and/or Taxanes January 2013 December 2016
NCT01590732 Completed Phase 1 Romidepsin, Ifosfamide, Carboplatin, and Etoposide in Treating Participants With Relapsed or Refractory Peripheral T-Cell Lymphoma October 29, 2012 May 2, 2018
NCT01614197 Completed Phase 1 A Trial of Temsirolimus With Etoposide and Cyclophosphamide in Children With Relapsed Acute Lymphoblastic Leukemia and Non-Hodgkins Lymphoma July 3, 2015 September 4, 2020
NCT01642251 Completed Phase 1/Phase 2 Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung Cancer September 28, 2012 July 2, 2018
NCT01775475 Completed Phase 2 Intravenous Chemotherapy or Oral Chemotherapy in Treating Patients With Previously Untreated Stage III-IV HIV-Associated Non-Hodgkin Lymphoma September 15, 2016 July 15, 2021
NCT01681537 Completed Phase 1 Lenalidomide Plus Chemotherapy for AML September 2012 December 2015
NCT01700946 Completed Phase 2 Therapy for Pediatric Relapsed or Refractory Precursor B-Cell Acute Lymphoblastic Leukemia and Lymphoma April 15, 2013 July 24, 2021
NCT01729845 Completed Phase 1/Phase 2 Decitabine Followed by Mitoxantrone Hydrochloride, Etoposide, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes December 20, 2012 April 3, 2017
NCT01760226 Completed Early Phase 1 Dose Adjusted EPOCH-R, to Treat Mature B Cell Malignancies January 2013 December 2016
NCT00000807 Completed Phase 2 Phase II Evaluation of Low-Dose Oral Etoposide for the Treatment of Relapsed or Progressed AIDS-Related Kaposi's Sarcoma After Systemic Chemotherapy July 2000
NCT00002003 Completed Phase 2 Phase II Study of Novantrone(R) (Mitoxantrone) and Etoposide in Patients With HIV Associated Large Cell and Immunoblastic Lymphomas
NCT00002461 Completed Phase 2 Combination Chemotherapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Refractory Hodgkin's Disease or Non-Hodgkin's Lymphoma April 1988 July 1991
NCT00002466 Completed Phase 2 Combination Chemotherapy and Radiation Therapy in Treating Patients With Peripheral Neuroectodermal Tumors, Ewing's Sarcoma, Wilms' Tumor, or Bone Cancer May 1990 May 2005
NCT00002471 Completed Phase 2 Combination Chemotherapy in Treating Patients With Acute B-Lymphoblastic Leukemia or Non-Hodgkin's Lymphoma February 1990 January 2003
NCT00002472 Completed Phase 2 Cisplatin and Etoposide Prior to Radiation Therapy in Treating Patients With CNS Tumors March 1991 August 2005
NCT00000660 Completed Phase 1 Phase I Study of Weekly Oral VP-16 for AIDS-Associated Kaposi's Sarcoma July 1992
NCT06309732 Completed Phase 2 GAMEC-II, Risk-adapted Protocol for Relapsed Germ Cell Tumours (GCT) July 2006 January 2014
NCT06049966 Completed Phase 1 Atezolizumab in Large Cell Neuroendocrine Carcinoma March 1, 2018 May 1, 2023
NCT00002489 Completed Phase 2 Combination Chemotherapy in Treating Children With Non-testicular Malignant Germ Cell Tumors October 1991 June 2002
NCT00002494 Completed Phase 2 Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma or Acute Lymphocytic Leukemia May 1992 January 2006
NCT00002508 Completed Phase 1/Phase 2 Combination Chemotherapy Followed by Bone Marrow or Stem Cell Transplantation in Treating Patients With Relapsed or Refractory Germ Cell Tumors November 1990 September 2001
NCT00002509 Completed Phase 1/Phase 2 High-Dose Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Poor-Prognosis Breast Cancer November 1991 December 2003
NCT00002510 Completed Phase 1/Phase 2 Chemotherapy and Radiation Therapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Non-Hodgkin's Lymphoma April 1992 June 2001
NCT00002514 Completed Phase 3 Stem Cell Transplantation Compared With Standard Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia in First Remission May 7, 1993
NCT00002517 Completed Phase 3 Combination Chemotherapy in Treating Children With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome March 1993
NCT00002521 Completed Phase 2 Combination Chemotherapy and Bone Marrow and/or Peripheral Stem Cell Transplantation in Treating Patients With Non-Hodgkin's Lymphoma February 1993 February 2000
NCT00002522 Completed Phase 2 Combination Chemotherapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma February 1993 February 2002
NCT00002524 Completed Phase 2 Combination Chemotherapy in Treating Patients With AIDS-Related Lymphoma June 1993 October 2005
NCT05116007 Completed Phase 1 Anti-PD-1 and VEGF Bispecific Antibody AK112 in Combination With Chemotherapy in Patients With ES-SCLC March 29, 2021 December 4, 2023
NCT00002550 Completed Phase 3 Chemotherapy Plus Radiation Therapy With or Without Surgery in Treating Patients With Stage IIIA Non-small Cell Lung Cancer March 1994 November 2013
NCT00002552 Completed Phase 2 Chemotherapy Plus Bone Marrow Transplantation in Treating Patients With Refractory Non-Hodgkin's Lymphoma, Hodgkin's Disease, or Multiple Myeloma October 1993 October 2003
NCT00002558 Completed Phase 1/Phase 2 Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Germ Cell Tumors January 1994 April 2009
NCT00002565 Completed Phase 3 Combination Chemotherapy in Treating Patients With Intermediate-Grade or Immunoblastic Non-Hodgkin's Lymphoma May 25, 1994 February 5, 2007
NCT00002566 Completed Phase 3 Combination Chemotherapy With Bone Marrow Transplantation in Treating Men With Germ Cell Tumors February 1994 December 2003
NCT00002567 Completed Phase 2 High-Dose Chemotherapy and Radiation Therapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Acute Leukemia in Remission March 1994 November 2000
NCT00002571 Completed Phase 2 SWOG-9320 Combination Chemotherapy, Radiation Therapy, and Antiviral Therapy in Treating Patients With AIDS-Related Lymphoma June 1994 July 2011
NCT00002588 Completed Phase 1 Combination Chemotherapy in Treating Patients With Recurrent or Refractory Leukemia August 1994 January 2001
NCT00002590 Completed Phase 2 Combination Chemotherapy in Treating Children With Lymphoma July 1994 March 2007
NCT00002596 Completed Phase 3 Combination Chemotherapy With or Without Bone Marrow or Stem Cell Transplantation in Treating Men With Untreated Germ Cell Tumors September 1994 July 2006
NCT00002598 Completed Phase 2 Combination Chemotherapy and Interferon Alfa in Treating Patients With Chronic Myelogenous Leukemia June 1994 June 2004
NCT00002610 Completed Phase 3 Chemotherapy With or Without Surgery, Radiation Therapy, or Stem Cell Transplantation in Treating Young Patients With Kidney Tumors January 1996 February 2006
NCT00002611 Completed Phase 3 Combination Chemotherapy Alone or With Radiation Therapy in Treating Children With Kidney Cancer July 1995 August 2003
NCT00002634 Completed Phase 2 Chemotherapy, Radiation Therapy, Immunotherapy, and Bone Marrow Transplantation in Treating Patients With Neuroblastoma February 1995 September 2004
NCT00002638 Completed Phase 2 Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Children With Relapsed Acute Lymphocytic Leukemia March 1995 March 2005
NCT00002642 Completed Phase 2 SWOG-9416: Chemotherapy, Radiation Therapy, and Surgery in Treating Patients With Stage III Non-small Cell Lung Cancer April 1995 July 2004
NCT00002643 Completed Phase 2 Combination Chemotherapy in Treating Patients With Newly Diagnosed Metastatic Ewing's Sarcoma or Primitive Neuroectodermal Tumor April 1995
NCT00002649 Completed Phase 3 Interleukin-2 or Observation Following Radiation Therapy, Combination Chemotherapy, and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent Non-Hodgkin's Lymphoma May 1995
NCT00002657 Completed Phase 2 SWOG-9239 Reduction of Immunosuppression Plus Interferon Alfa and Combination Chemotherapy in Treating Patients With Malignant Tumors That Develop After Organ Transplant May 1995 July 2011
NCT05026593 Completed Phase 1 A Study of IBI110 in Combination With Sintilimab and Chemotherapy in Patients With Untreated Extensive-Stage Small Cell Lung Cancer September 7, 2021 June 26, 2023
NCT00002665 Completed Phase 2 SWOG-9400 Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Patients With Previously Untreated Acute Lymphocytic Leukemia July 1995 December 2003
NCT00002674 Completed Phase 2 Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Chronic Myelogenous Leukemia October 1994 March 2000
NCT00002675 Completed Phase 2 Chemotherapy in Treating Patients With Retinoblastoma May 1995 January 2001
NCT00002691 Completed Phase 2 Combination Chemotherapy in Treating Pediatric Patients With Stage III or IV Non-Hodgkin's Lymphoma August 1995 June 2000
NCT00002697 Completed Phase 2 Combination Chemotherapy Plus Radiation Therapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Non-Hodgkin's Lymphoma September 1995 June 2003
NCT00002704 Completed Phase 2 Radiation Therapy and Chemotherapy in Treating Children With CNS Relapse From Acute Lymphoblastic Leukemia January 1996
NCT00002714 Completed Phase 2 Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Early-Stage Hodgkin's Disease April 1995 September 2001
NCT00002715 Completed Phase 2 Combination Chemotherapy in Treating Patients With Advanced Hodgkin's Lymphoma April 1989 October 2015
NCT00002719 Completed Phase 3 Combination Chemotherapy With or Without G-CSF in Treating Older Patients With Acute Myeloid Leukemia December 1995
NCT00002740 Completed Phase 1 Combination Chemotherapy Plus Peripheral Stem Cell Transplantation Followed by Surgery and/or Radiation Therapy in Treating Young Patients With Advanced Neuroblastoma May 1996 September 2005
NCT00002756 Completed Phase 2 Induction Intensification in Treating Infants With Newly Diagnosed Acute Lymphoblastic Leukemia June 1996 March 2012
NCT00002757 Completed Phase 3 TITLE:Less Intensive Therapy for Children With Non-Hodgkin's Lymphoma June 2001 October 2009
NCT00002766 Completed Phase 3 Comparison of Two Combination Chemotherapy Regimens in Treating Adults With Previously Untreated Leukemia or Lymphoma March 1996 September 2011
NCT00002768 Completed Phase 2 Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Acute Myeloid Leukemia in Second Remission June 1996 March 2009
NCT00002785 Completed Phase 2 Combination Chemotherapy, Bone Marrow Transplantation, and Radiation Therapy in Treating Infants With Acute Lymphoblastic Leukemia July 1996 March 2007
NCT00002788 Completed Phase 1 High-Dose Chemotherapy Followed by Total-Body Irradiation and Peripheral Stem Cell Transplantation in Treating Patients With Chronic Lymphocytic Leukemia October 1995 September 2002
NCT00002798 Completed Phase 3 Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Children With Acute Myelogenous Leukemia or Myelodysplastic Syndrome August 1996
NCT00002800 Completed Phase 2 Chemotherapy in Treating Patients With Newly Diagnosed Acute or Chronic Myelogenous Leukemia or Myelodysplastic Syndrome July 1996 March 2003
NCT00002802 Completed Phase 3 Therapy Based on Stage of Disease and Risk Assessment in Treating Children With Neuroblastoma July 1990 September 2003
NCT00002805 Completed Phase 2 Combination Chemotherapy in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome August 1997 June 2008
NCT00002816 Completed Phase 3 Combination Chemotherapy in Treating Children With Relapsed Acute Lymphoblastic Leukemia December 1996 April 2006
NCT00002822 Completed Phase 3 Combination Chemotherapy Followed by Radiation Therapy in Patients With Small Cell Lung Cancer March 1996 November 2005
NCT00002823 Completed Phase 3 Combination Chemotherapy Compared With No Treatment Following Surgery in Treating Patients With Non-small Cell Lung Cancer February 1995
NCT00002827 Completed Phase 3 Chemotherapy Followed by Radiation Therapy in Treating Young Patients With Newly Diagnosed Hodgkin's Disease October 1996 June 2008
NCT00002829 Completed Phase 2 Bone Marrow Transplantation in Treating Patients With Lymphoma February 1994 April 2002
NCT00002836 Completed Phase 3 Filgrastim Plus Chemotherapy Compared With Filgrastim Alone In Treating Women Undergoing Peripheral Stem Cell Transplantation For Breast Cancer September 26, 1995 March 9, 2006
NCT00002854 Completed Phase 1 High-Dose Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Advanced Cancer December 1994 August 2015
NCT04933617 Completed Phase 1 Copanlisib With Dose-Adjusted EPOCH-R in Relapsed and Refractory Burkitt Lymphoma and Other High-Grade B-cell Lymphomas March 24, 2022 November 30, 2023
NCT00002865 Completed Phase 2 High-Intensity, Brief-Duration Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphocytic Leukemia April 1995 August 2001
NCT00002868 Completed Phase 3 Interferon-alfa With or Without Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Newly Diagnosed Chronic Myelogenous Leukemia November 20, 1997
NCT00002876 Completed Phase 2 Etoposide Plus Cisplatin in Treating Patients With Recurrent Ependymomas October 1991 January 2005
NCT00002898 Completed Phase 3 Surgery Followed by Chemotherapy in Treating Young Patients With Soft Tissue Sarcoma January 1995 December 2009
NCT04878016 Completed Phase 3 A Study of Carboplatin Plus Etoposide With or Without ZKAB001 (Anti-PD-L1 Antibody) in Patients With ES-SCLC July 15, 2021 October 13, 2023
NCT00002912 Completed Phase 1 Combination Chemotherapy Plus PSC-833 in Treating Children With Refractory or Relapsed Acute Leukemia January 1997
NCT00002925 Completed Phase 1/Phase 2 Combination Chemotherapy Plus PSC 833 Followed by Interleukin-2 in Treating Patients With Acute Myelogenous Leukemia February 1997 June 2010
NCT04778410 Completed Phase 2 Study of Magrolimab Combinations in Participants With Myeloid Malignancies June 28, 2021 March 1, 2024
NCT00002931 Completed Phase 2 Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Relapsed Germ Cell Cancer February 1997 December 2014
NCT00002936 Completed Phase 1 Altretamine and Etoposide in Treating Patients With HIV-Related Cancer July 1996
NCT00002941 Completed Phase 2 Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Children With Recurrent or Refractory Hodgkin's or Non-Hodgkin's Lymphoma April 1998 March 2007
NCT00002943 Completed Phase 2 Carboplatin, Etoposide, Cyclophosphamide, and Autologous Bone Marrow Transplantation in Patients With Relapsed or Refractory Cancer February 1993 August 2007
NCT00002945 Completed Phase 3 High Dose Chemotherapy, Peripheral Stem Cell Transplantation, and Interleukin-2 in Treating Patients With Acute Myeloid Leukemia December 1996 August 2011
NCT00002974 Completed Phase 2 Whole-Body Hyperthermia Plus Chemotherapy in Treating Patients With Advanced Sarcoma July 1996 April 2003
NCT00002982 Completed Phase 2 Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Older Patients With Refractory or Relapsed Intermediate-Grade Non-Hodgkin's Lymphoma January 1997 October 2005
NCT00003052 Completed Phase 3 Combination Chemotherapy With or Without Hyperthermia Therapy in Treating Patients With Soft Tissue Sarcoma July 1997 June 2010
NCT00003084 Completed Phase 2 Combination Chemotherapy With Ketoconazole in Treating Patients With Prostate Cancer December 1997 November 2002
NCT00003093 Completed Phase 3 Combination Chemotherapy in Treating Children With Neuroblastoma March 1988 January 2011
NCT04712903 Completed Phase 3 Durvalumab Plus Chemotherapy in Untreated Patients With Extensive-Stage Small Cell Lung Cancer December 16, 2020 June 21, 2023
NCT00003114 Completed Phase 2 Combination Chemotherapy in Treating Patients With AIDS-Related Hodgkin's Disease July 1997 February 2003
NCT00003119 Completed Phase 3 Surgery in Treating Children With Neuroblastoma March 1998 March 2006
NCT00003141 Completed Phase 1 Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Infants With Malignant Brain or Spinal Cord Tumors March 1998 October 2011
NCT00003158 Completed Phase 2 S9712: Radiation Therapy and Combination Chemotherapy in Treating Patients With Stage III Non-small Cell Lung Cancer February 1998 December 2007
NCT00003190 Completed Phase 3 Combination Chemotherapy With or Without Valspodar in Treating Patients With Previously Untreated Acute Myeloid Leukemia January 1998
NCT00003215 Completed Phase 3 Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Newly Diagnosed Aggressive Non-Hodgkin's Lymphoma April 1997 March 2004
NCT00003243 Completed Phase 1 Combination Chemotherapy Plus Infusion of White Blood Cells in Treating Patients With Hematologic Cancer January 1998
NCT00003269 Completed Phase 2 Amifostine Followed by High Dose Chemotherapy in Treating Patients With Hematologic Cancer or Solid Tumors February 1998 January 2001
NCT04631029 Completed Phase 1 Testing the Addition of an Anti-cancer Drug, Entinostat, to the Usual Chemotherapy and Immunotherapy Treatment (Atezolizumab, Carboplatin and Etoposide) for Previously Untreated Aggressive Lung Cancer That Has Spread April 27, 2021 July 11, 2023
NCT00003299 Completed Phase 3 Cisplatin Plus Etoposide With or Without Paclitaxel in Treating Patients With Extensive-Stage Small Cell Lung Cancer April 1998 January 2006
NCT00003309 Completed Phase 2 Combination Chemotherapy Plus Radiation Therapy in Treating Adult Patients With Brain Cancer May 4, 1999
NCT00003364 Completed Phase 3 Radiation Therapy Plus Combination Chemotherapy In Treating Patients With Limited Stage Small Cell Lung Cancer January 1993 August 2006
NCT00003389 Completed Phase 3 Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Hodgkin's Lymphoma June 17, 1999 May 2016
NCT00003397 Completed Phase 2 Peripheral Stem Cell Transplantation Plus Combination Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma September 1998 December 2002
NCT00003399 Completed Phase 2 Peripheral Stem Cell Transplantation Plus Combination Chemotherapy in Treating Patients With Multiple Myeloma September 1998 September 2002
NCT00003401 Completed Phase 2 Peripheral Stem Cell Transplantation Plus Combination Chemotherapy in Treating Patients With Multiple Myeloma January 1999 September 2002
NCT00003402 Completed Phase 2 Peripheral Stem Cell Transplantation Plus Combination Chemotherapy in Treating Patients With Low-Grade Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia January 1999 December 2002
NCT00003421 Completed Phase 3 Combination Chemotherapy in Treating Patients With Advanced Hodgkin's Disease June 1998 November 2005
NCT00003436 Completed Phase 3 Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Children With Acute Myeloid Leukemia July 1998 December 2005
NCT00003541 Completed Phase 1/Phase 2 Combination Chemotherapy, Radiation Therapy, and Peripheral Stem Cell Transplantation in Treating Patients With Stage III or Stage IV Mantle Cell Lymphoma June 1998 July 2006
NCT00003573 Completed Phase 2 Etoposide Plus Radiation Therapy Followed by Combination Chemotherapy in Treating Children With Newly Diagnosed Advanced Medulloblastoma November 1998 March 2008
NCT00003575 Completed Phase 2 Interleukin-12 Following Chemotherapy in Treating Patients With Refractory HIV-Associated Non-Hodgkin's Lymphoma January 1999
NCT04154189 Completed Phase 2 A Study to Compare the Efficacy and Safety of Ifosfamide and Etoposide With or Without Lenvatinib in Children, Adolescents and Young Adults With Relapsed and Refractory Osteosarcoma March 23, 2020 August 17, 2023
NCT00003597 Completed Phase 1 Colony-Stimulating Factors in Treating Children With Recurrent or Refractory Solid Tumors November 1998 September 2005
NCT00003606 Completed Phase 3 Combination Chemotherapy in Treating Patients With Extensive Stage Small Cell Lung Cancer March 1996 June 2001
NCT00003619 Completed Phase 1/Phase 2 Combination Chemotherapy Followed By Peripheral Stem Cell Transplantation or Isotretinoin in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Acute Lymphocytic Leukemia February 1998 April 2004
NCT00003621 Completed Phase 2 Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Anaplastic Astrocytoma February 1999 July 2005
NCT00003625 Completed Phase 1 Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Newly Diagnosed Brain Stem Glioma December 1998 April 2006
NCT00003631 Completed Phase 2 Chemotherapy Plus Radiation Therapy in Treating Patients With Refractory or Relapsed Hodgkin's Lymphoma August 1998
NCT00003632 Completed Phase 2 Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Newly Diagnosed Central Nervous System Lymphoma September 1998
NCT00003650 Completed Phase 3 Combination Chemotherapy in Treating Children With Non-Hodgkin's Lymphoma February 1997 November 2013
NCT00003657 Completed Phase 2 High-dose ICE With Amifostine July 1998 June 2002
NCT06418594 Not yet recruiting Phase 2 Adebrelimab Plus Apatinib and Etoposide for the Treatment of HER2-Negative Breast Cancer Brain Metastasis May 15, 2024 December 31, 2026
NCT03628131 Not yet recruiting Phase 1/Phase 2 Combination Chemotherapy With Pazopanib in Children and Adolescents With Relapsed/Refractory Solid Tumors October 2018 July 2025
NCT03669783 Not yet recruiting Phase 3 Clinical Trial for Patients With a Stage IV Childhood Renal Tumor, Comparing Upfront Vincristine, Actinomycin-D and Doxorubicin (Standard Arm) With Upfront Vincristine, Carboplatin and Etoposide (Experimental Arm) January 1, 2019 January 1, 2027
NCT04683198 Not yet recruiting Phase 2 Camrelizumab Combined With Apatinib ,Carboplatin and Etoposide in Participants With ES-SCLC April 1, 2021 June 30, 2024
NCT05006664 Not yet recruiting Phase 2 Brentuximab Vedotin in Combination With CHEP in Patient With PTCL October 2021 October 2024
NCT05142865 Not yet recruiting Phase 2 Camrelizumab Combined With Chemotherapy and Apatinib for Extrapulmonary Neuroendocrine Carcinomas January 14, 2022 December 31, 2024
NCT05590572 Not yet recruiting Phase 1/Phase 2 A Study of Sulfatinib on Relapsed or Refractory Drug Resistant Osteosarcoma January 2023 December 2027
NCT05776407 Not yet recruiting Phase 1/Phase 2 Safety, Efficacy and Pharmacokinetics of ThisCART19A in Patients With Refractory or Relapsed B Cell Lymphoma May 2023 November 2024
NCT05784987 Not yet recruiting N/A R-MINE+X in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma April 15, 2023 January 1, 2025
NCT05863845 Not yet recruiting N/A Efficacy and Safety of Venetoclax Combined With BEAM Pretreatment in Autologous Transplantation for DLBCL June 1, 2023 November 30, 2025
NCT05991388 Not yet recruiting Phase 2/Phase 3 A Global Study of Novel Agents in Paediatric and Adolescent Relapsed and Refractory B-cell Non-Hodgkin Lymphoma May 2024 May 2033
NCT06160791 Not yet recruiting Phase 2 Ruxolitinib With De-Intensified HLH-94 for the Treatment of Hemophagocytic Lymphohistiocytosis (HLH) February 1, 2024 May 31, 2027
NCT06249191 Not yet recruiting Phase 1/Phase 2 Mosunetuzumab With Chemotherapy for the Treatment of Patients With Untreated C-Myc Rearrangement Positive High Grade B Cell Lymphoma or Diffuse Large B Cell Lymphoma May 31, 2024 April 1, 2027
NCT06362252 Not yet recruiting Phase 1/Phase 2 A Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance in Subjects With Extensive Stage-Small Cell Lung Cancer (IDeate-Lung03) June 17, 2024 December 30, 2026
NCT06368817 Not yet recruiting Phase 2 A Study of Lower Radiotherapy Dose to Treat Children With CNS Germinoma July 12, 2024 November 4, 2033
NCT06377540 Not yet recruiting Phase 2 MT2022-60: Ph 2 Study of Pembro+ BEAM With ASCT for Relapsed Hodgkin Lymphoma August 1, 2024 September 1, 2027
NCT06401330 Not yet recruiting Phase 3 A Study Using Risk Factors to Determine Treatment for Children With Favorable Histology Wilms Tumors (FHWT) June 12, 2024 February 13, 2031
NCT06406465 Not yet recruiting Phase 2 A UGT1A1 Genotype-Directed Study of Belinostat Pharmacokinetics and Toxicity June 23, 2024 July 30, 2028
NCT05068232 Recruiting Phase 2 Durvalumab and Ablative Radiation in Small Cell Lung Cancer (DARES) August 19, 2022 October 1, 2027
NCT02861573 Recruiting Phase 1/Phase 2 Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365) November 17, 2016 October 22, 2027
NCT05019716 Recruiting Phase 1/Phase 2 Testing the Safety and Efficacy of the Addition of A New Anti-cancer Drug, ZEN003694, to Chemotherapy Treatment (Etoposide and Cisplatin) for Adult and Pediatric Patients (12-17 Years) With NUT Carcinoma July 13, 2022 December 1, 2024
NCT02870907 Recruiting Phase 2 Adjuvant Treatment in Extensive Unilateral Retinoblastoma Primary Enucleated (RB SFCE 2009) March 2010 September 2030
NCT06217757 Recruiting Phase 1/Phase 2 Safety and Tolerability of LDRT+Sugemalimab+Chemotherapy+Olaparib for First-Line Treatment of SLFN-11 Positive ES-SCLC April 18, 2024 March 20, 2027
NCT06110572 Recruiting Phase 1/Phase 2 Phase I/II Trial in ES-SCLC to Enhance Response to Atezolizumab Plus Chemotherapy With Total Body Irradiation July 31, 2024 June 30, 2028
NCT06091124 Recruiting Phase 2 Neoadjuvant Adebrelimab Plus Etoposide and Cisplatin in Neuroendocrine Bladder Carcinoma November 16, 2023 December 31, 2026
NCT02905110 Recruiting Early Phase 1 Methotrexate and Etoposide Infusions Into the Fourth Ventricle in Children With Recurrent Posterior Fossa Brain Tumors October 2016 November 2025
NCT04981899 Recruiting Phase 1/Phase 2 A Study of Safety and Efficacy of PET-adapted Treatment With Nivolumab at the Fixed Dose 40 mg, Ifosfamide, Carboplatin, Etoposide (NICE-40) in Patients With Relapsed/Refractory Hodgkin Lymphoma March 1, 2021 October 1, 2024
NCT05765825 Recruiting Phase 2 Study of Low-Dose Radiotherapy Concurrent Cisplatin/Carboplatin Plus Etoposide With Serplulimab for Patients With ES-SCLC March 7, 2023 December 2025
NCT04947501 Recruiting Early Phase 1 A Study of N9 Chemotherapy in Children With Neuroblastoma June 22, 2021 June 22, 2025
NCT04923776 Recruiting Phase 2 Liver Directed RT + Chemo-immunotherapy for ES-SCLC September 20, 2021 February 2025
NCT02429687 Recruiting Phase 3 TC or BEP in Treating Patients With Malignant Ovarian Germ Cell Tumors April 2015 May 2030
NCT02429700 Recruiting Phase 3 TC or BEP in Treating Patients With Ovarian Malignant Sex Cord-Stromal Tumors April 2015 May 2030
NCT04871607 Recruiting Phase 2 Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined With BEAM Chemotherapy Conditioning for the Treatment of Primary Refractory or Relapsed Hodgkin Lymphoma November 2, 2021 October 2, 2027
NCT01356290 Recruiting Phase 2 Antiangiogenic Therapy for Children With Recurrent Medulloblastoma, Ependymoma and ATRT April 2014 April 2026
NCT04833114 Recruiting Phase 3 Polatuzumab Vedotin Plus Rituximab, Ifosfamide, Carboplatin and Etoposide (Pola-R-ICE) Versus R-ICE Alone in Second Line Treatment of Diffuse Large B-cell Lymphoma (DLBCL) April 30, 2021 December 31, 2025
NCT03007147 Recruiting Phase 3 Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia August 8, 2017 September 30, 2027
NCT02436707 Recruiting Phase 2 Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma October 27, 2015 December 31, 2026
NCT06077500 Recruiting Phase 1 DAREONᵀᴹ-8: A Study to Test How Well Different Doses of BI 764532 in Addition to Standard of Care Are Tolerated by People With Advanced Small Cell Lung Cancer January 11, 2024 June 25, 2026
NCT04804007 Recruiting Phase 2 Maintenance Oral Etoposide or Observation Following High-dose Chemo for GCT March 3, 2021 December 2028
NCT04803201 Recruiting Phase 2 Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma July 30, 2021 January 1, 2026
NCT05903092 Recruiting Phase 2 MOnaliZumab in Combination With durvAlumab (MEDI4736) Plus Platinum-based chemotheRapy for First-line Treatment of Extensive Stage Small Cell Lung Cancer September 26, 2023 June 30, 2025
NCT01887340 Recruiting Phase 2 Therapeutic Strategy Guided by PET-TDM for Patients With Seminoma June 2013 June 2026
NCT04765098 Recruiting Phase 2 Tamoxifen Versus Etoposide After First Recurrence in GBM Patients January 28, 2022 December 2026
NCT06262438 Recruiting Phase 2 CHIP-AML22/Quizartinib: Quizartinib + Chemotherapy in Newly Diagnosed Pediatric FLT3-ITD+ and NPM1wt AML Patients February 6, 2024 June 2032
NCT01704716 Recruiting Phase 3 High Risk Neuroblastoma Study 1.8 of SIOP-Europe (SIOPEN) February 2002 September 2026
NCT05844150 Recruiting Phase 2/Phase 3 A Study of PM8002 (Anti-PD-L1/VEGF) in Combination With Chemotherapy in Patients With ES-SCLC June 1, 2023 December 2025
NCT04728230 Recruiting Phase 1/Phase 2 Olaparib and Durvalumab With Carboplatin, Etoposide, and/or Radiation Therapy for the Treatment of Extensive-Stage Small Cell Lung Cancer, PRIO Trial January 5, 2021 December 31, 2025
NCT04702880 Recruiting Phase 2 A Study of BMS-986012 in Combination With Carboplatin, Etoposide, and Nivolumab as First-line Therapy in Extensive-stage Small Cell Lung Cancer March 17, 2021 December 31, 2025
NCT04699838 Recruiting Phase 2 Chemo-Immunotherapy Followed by Durvalumab and Ceralasertib in Treatment Naïve Patients With Extensive Stage Small Cell Lung Cancer April 20, 2021 September 2024
NCT03067181 Recruiting Phase 3 Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors May 25, 2017 June 30, 2027
NCT04696575 Recruiting Phase 2 Lamivudine in Combination With Chemoimmunotherapy for the Treatment of Extensive Stage Small Cell Lung Cancer July 2, 2021 July 1, 2026
NCT05675410 Recruiting Phase 3 A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab May 11, 2023 April 28, 2031
NCT04684368 Recruiting Phase 2 A Study of a New Way to Treat Children and Young Adults With a Brain Tumor Called NGGCT July 13, 2021 December 21, 2029
NCT06177925 Recruiting Phase 2 A Phase Ⅱ Clinical Study of Adebrelimab Combined With Chemotherapy and Concurrent Radiotherapy for Extensive-Stage Oligometastatic SCLC December 10, 2023 September 30, 2026
NCT05664971 Recruiting Phase 1/Phase 2 JS004 Combined With Toripalimab and With Standard Chemotherapy Treat Patients With Advanced Lung Cancer February 9, 2023 November 17, 2024
NCT03117010 Recruiting Prospective Cohort for Adult Hemophagocytosis January 1, 2017 December 31, 2024
NCT04679012 Recruiting Phase 2 Polatuzumab Vedotin in Combination With Chemotherapy in Subjects With Richter's Transformation September 24, 2021 September 2026
NCT04638790 Recruiting Phase 3 First Line Chemotherapy for Classical Hodgkin Lymphoma in Russia (HL-Russia-1) February 1, 2020 December 31, 2026
NCT03125642 Recruiting Phase 2 Auto Stem Cell Transplant for Lymphoma Patients April 20, 2017 April 30, 2026
NCT04585893 Recruiting Phase 2 Safety and Efficacy of Rituximab for Treatment of Multicentric Castleman Disease in Malawi June 22, 2021 August 2026
NCT03136146 Recruiting Phase 2 Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia August 9, 2017 August 1, 2026
NCT04560972 Recruiting Phase 1 LB-100, Carboplatin, Etoposide, and Atezolizumab for the Treatment of Untreated Extensive-Stage Small Cell Lung Cancer May 28, 2021 March 9, 2026
NCT04551131 Recruiting Phase 1/Phase 2 Use Of A Response-Adapted Ruxolitinib-Containing Regimen For The Treatment Of Hemophagocytic Lymphohistiocytosis July 13, 2021 August 2026
NCT05624996 Recruiting Phase 3 Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-small Cell Lung Cancer May 10, 2023 October 15, 2036
NCT03206671 Recruiting Phase 3 Treatment Protocol of the NHL-BFM and the NOPHO Study Groups for Mature Aggressive B-cell Lymphoma and Leukemia in Children and Adolescents August 3, 2017 August 2024
NCT03220022 Recruiting Phase 1 Ibrutinib, Rituximab, Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With HIV-Positive Stage II-IV Diffuse Large B-Cell Lymphomas March 16, 2018 June 20, 2025
NCT05106296 Recruiting Phase 1 Chemo-immunotherapy Using Ibrutinib Plus Indoximod for Patients With Pediatric Brain Cancer February 8, 2022 September 2026
NCT05058651 Recruiting Phase 2/Phase 3 Evaluating the Addition of the Immunotherapy Drug Atezolizumab to Standard Chemotherapy Treatment for Advanced or Metastatic Neuroendocrine Carcinomas That Originate Outside the Lung June 28, 2022 October 1, 2028
NCT04543890 Recruiting Phase 2 A Prospective Study Comparing Two Radiotherapy Dose/Fraction and Omitting CTVs of the Primary Tumor in Limited SCLC May 1, 2018 June 1, 2025
NCT04530487 Recruiting Phase 2 Donor Stem Cell Transplant After Chemotherapy for the Treatment of Recurrent or Refractory High-Risk Solid Tumors in Pediatric and Adolescent-Young Adults August 19, 2020 May 9, 2025
NCT04469530 Recruiting Phase 2 Sirolimus in Combination With Metronomic Chemotherapy in Children With High-Risk Solid Tumors September 16, 2020 September 2025
NCT04432714 Recruiting Phase 1/Phase 2 Lenalidomide in Combination With R-DA-EPOCH in Patients With Untreated DLBCL With MYC Rearrangement June 9, 2020 December 31, 2026
NCT04322318 Recruiting Phase 2 A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWT October 19, 2020 July 1, 2027
NCT05832320 Recruiting N/A Optimum Induction Therapy of Low-risk APL January 1, 2023 December 31, 2024
NCT03418038 Recruiting Phase 2 Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia March 23, 2018 March 2026
NCT03420963 Recruiting Phase 1 Donor Natural Killer Cells, Cyclophosphamide, and Etoposide in Treating Children and Young Adults With Relapsed or Refractory Solid Tumors August 31, 2018 December 1, 2027
NCT04301076 Recruiting Phase 1 Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment ("EPOCH") for Adult T-Cell Leukemia-Lymphoma (ATL) August 31, 2021 December 31, 2025
NCT04221035 Recruiting Phase 3 High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN) November 5, 2019 November 2032
NCT04177004 Recruiting Phase 1 Human Lysozyme Goat Milk for the Prevention of Graft Versus Host Disease in Patients With Blood Cancer Undergoing a Donor Stem Cell Transplant April 30, 2021 December 31, 2024
NCT05605899 Recruiting Phase 3 Study to Compare Axicabtagene Ciloleucel With Standard of Care Therapy as First-line Treatment in Participants With High-risk Large B-cell Lymphoma February 10, 2023 March 2031
NCT04139304 Recruiting Early Phase 1 A Study of Daratumumab and Dose-Adjusted EPOCH in Plasmablastic Lymphoma May 24, 2021 August 2027
NCT04129710 Recruiting Phase 2 A Trial to Compare Ibrutinib Versus Lenalidomide in Combination With MRE-chemotherapy for Adult Patients With Recurrent/Refractory Primary Central Nervous System Lymphoma (PCNSL) January 1, 2020 December 31, 2025
NCT04049669 Recruiting Phase 2 Pediatric Trial of Indoximod With Chemotherapy and Radiation for Relapsed Brain Tumors or Newly Diagnosed DIPG October 2, 2019 October 2, 2027
NCT04044222 Recruiting Phase 3 A Study to Evaluate the Efficacy and Safety of a Sintilimab Plus ICE Regimen Versus ICE Regimen in Classic Hodgkin's Lymphoma Patients (cHL) Who Have Failed First-line Standard Chemotherapy October 21, 2019 December 31, 2024
NCT03926624 Recruiting Phase 3 Trial of DFP-10917 vs Non-Intensive or Intensive Reinduction for AML Patients in 2nd/3rd/4th Salvage November 22, 2019 December 2022
NCT03837873 Recruiting Phase 2 DLCL002 Protocol for Patients With High Risk Aggressive B-cell Lymphoma January 21, 2019 September 1, 2024
NCT03570983 Recruiting Phase 2 A Trial Comparing Single Agent Melphalan to Carmustine, Etoposide, Cytarabine, and Melphalan (BEAM) as a Preparative Regimen for Patients With Multiple Myeloma Undergoing High Dose Therapy Followed by Autologous Stem Cell Reinfusion September 5, 2018 December 2024
NCT03793478 Recruiting Phase 1/Phase 2 Safety and Efficacy of Quizartinib in Children and Young Adults With Acute Myeloid Leukemia (AML), a Cancer of the Blood August 15, 2018 May 1, 2027
NCT03755804 Recruiting Phase 2 Pediatric Classical Hodgkin Lymphoma Consortium Study: cHOD17 December 12, 2018 July 1, 2028
NCT03736616 Recruiting Phase 2 Acalabrutinib Plus RICE for Relapsed/Refractory DLBCL August 16, 2019 September 2023
NCT03583710 Recruiting Phase 3 Mitotane With or Without Cisplatin and Etoposide After Surgery in Treating Patients With Stage I-III Adrenocortical Cancer With High Risk of Recurrence August 20, 2018 January 22, 2025
NCT05821088 Recruiting Phase 2 Tafasitamab and Lenalidomide Followed by Tafasitamab and ICE as Salvage Therapy for Transplant Eligible Patients With Relapsed/ Refractory Large B-Cell Lymphoma June 29, 2023 December 31, 2025
NCT03591510 Recruiting Phase 2 A Global Study of Midostaurin in Combination With Chemotherapy to Evaluate Safety, Efficacy and Pharmacokinetics in Newly Diagnosed Pediatric Patients With FLT3 Mutated AML March 13, 2019 February 15, 2029
NCT03719105 Recruiting Early Phase 1 Chemoimmunotherapy and Allogeneic Stem Cell Transplant for NK T-cell Leukemia/Lymphoma March 1, 2019 December 31, 2026
NCT06372626 Recruiting Phase 1/Phase 2 Study of ZG005 in Combination With Etoposide and Cisplatin in Participants With Advanced Neuroendocrine Carcinoma. May 30, 2024 August 2026
NCT03643276 Recruiting Phase 3 Treatment Protocol for Children and Adolescents With Acute Lymphoblastic Leukemia - AIEOP-BFM ALL 2017 July 15, 2018 July 14, 2028
NCT06172296 Recruiting Phase 3 Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma April 19, 2024 December 31, 2029
NCT05600686 Recruiting Phase 2 Loncastuximab Tesirine and Rituximab Followed by DA-EPOCH-R for Treating Patients With High-Risk Diffuse Large B-cell Lymphoma May 24, 2023 February 1, 2028
NCT05595460 Recruiting Phase 1 Study of RYZ101 in Combination With SoC in Subjects With SSTR+ ES-SCLC October 10, 2022 December 2026
NCT05594290 Recruiting Phase 2 Chemo-immunotherapy in Patients With Resectable Merkel Cell Carcinoma Prior to Surgery December 7, 2022 November 2026
NCT06140966 Recruiting Phase 2 Study to Evaluate the Safety and Efficacy of Daratumumab and Carfilzomib-based Induction/Consolidation/Maintenance Therapy in Transplant-eligible, Ultra High-risk, Newly Diagnosed Multiple Myeloma October 20, 2023 October 20, 2027
NCT06230224 Recruiting Phase 3 A Trial to Learn How Effective and Safe Odronextamab is Compared to Standard of Care for Adult Participants With Previously Treated Aggressive B-cell Non-Hodgkin Lymphoma February 15, 2024 July 6, 2027
NCT02574728 Recruiting Phase 2 Sirolimus in Combination With Metronomic Chemotherapy in Children With Recurrent and/or Refractory Solid and CNS Tumors June 2015 February 2025
NCT05546060 Recruiting Phase 1 Efficacy and Safety of Venetoclax Combined With Dexamethasone and Etoposide in HLH July 1, 2022 October 1, 2025
NCT05536154 Recruiting N/A Etoposide+Cytarabine+PEG-rhG-CSF as First Line Mobilization Regimen of Hematopoietic Stem Cells in Patients With Hematological Malignancies November 1, 2022 October 2024
NCT06132113 Recruiting Phase 1 DAREON™-7: A Study to Test How Well Different Doses of BI 764532 in Addition to Chemotherapy Are Tolerated by People With Advanced Neuroendocrine Cancers December 20, 2023 December 1, 2025
NCT05535166 Recruiting Phase 2 Molecular and Clinical Risk-Directed Therapy for Infants and Young Children With Newly Diagnosed Medulloblastoma December 20, 2022 July 2035
NCT02605421 Recruiting Phase 2 Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma June 2016 July 2025
NCT05533775 Recruiting Phase 1/Phase 2 A Study to Evaluate Glofitamab Monotherapy and Glofitamab + Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma November 16, 2022 October 15, 2027
NCT05517213 Recruiting N/A High-dose Chemotherapy+G-CSF in Peripheral Blood Stem Cell Mobilization in Patients With Multiple Myeloma February 1, 2022 October 1, 2025
NCT05510089 Recruiting N/A Etoposide+Cytarabine+PEG-rhG-CSF for Hematopoietic Stem Cell Mobilization in Patients With Hematological Malignancies September 1, 2022 December 31, 2024
NCT05504291 Recruiting Phase 2 A Study to Give Treatment Inside the Eye to Treat Retinoblastoma November 4, 2022 December 31, 2026
NCT06140407 Recruiting Phase 2 Pembrolizumab After Radiation Therapy and Chemotherapy in Limited Stage Small Cell Lung Cancer May 8, 2024 May 31, 2029
NCT06039371 Recruiting Phase 2 Supraphysiological Androgen to Enhance Chemotherapy Treatment Activity in Metastatic Castration-Resistant Prostate Cancer, SPECTRA Study May 21, 2024 December 31, 2027
NCT02633514 Recruiting Phase 3 Adjuvant Treatment for Incomplete Resection Thymoma or Thymic Carcinoma December 1, 2023 December 2026
NCT05491304 Recruiting Phase 4 Cytokine Guided Risk Stratification and Treatment in Pediatric Hemophagocytic Lymphohistiocytosis September 1, 2022 December 31, 2025
NCT05466318 Recruiting Phase 3 ChiCGB vs BEAM in High-risk or R/R Lymphomas July 1, 2022 December 30, 2025
NCT02639650 Recruiting Phase 3 Study of Paclitaxel Plus Cisplatin as the First-line Chemotherapy in High Risk Gestational Trophoblastic Tumor March 1, 2016 March 1, 2026
NCT05815160 Recruiting Phase 1 Debio 0123 in Combination With Carboplatin and Etoposide in Adult Participants With Small Cell Lung Cancer That Recurred or Progressed After Previous Standard Platinum-Based Therapy May 2, 2023 April 2026
NCT05453500 Recruiting Phase 2 Chemotherapy (DA-EPOCH+/-R) and Targeted Therapy (Tafasitamab) for the Treatment of Newly-Diagnosed Philadelphia Chromosome Negative B Acute Lymphoblastic Leukemia March 27, 2023 September 1, 2030
NCT05389423 Recruiting Phase 1 Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas June 27, 2023 June 1, 2032
NCT05384821 Recruiting Phase 1/Phase 2 Metronomic Chemotherapy in Wilms Tumor (MetroWilms-1906) September 14, 2022 October 2028
NCT05800587 Recruiting Phase 2 Dose Attenuated Chemotherapy in Compromised Patients With Lung Cancer February 22, 2023 August 1, 2029
NCT02705508 Recruiting Phase 2 PEG-ASP, Etoposide and Gemcitabine for Natural Killer/T Lymphoma February 2016 December 2023
NCT06256237 Recruiting Phase 2 Neoadjuvant Therapy With Toripalimab and JS004 Combined With Etoposide and Platinum Chemotherapy for Limited-stage Small Cell Lung Cancer : A Phase 2 Trial April 1, 2024 January 31, 2032
NCT05384015 Recruiting Phase 2 Study of Pembrolizumab, Lenvatinib and Chemotherapy Combination in First Line Extensive-stage Small Cell Lung Cancer November 7, 2022 July 30, 2027
NCT05364424 Recruiting Phase 1 A Study Evaluating the Efficacy, Safety, and Pharmacokinetics of Glofitamab in Combination With Rituximab Plus Ifosfamide, Carboplatin Etoposide Phosphate in Participants With Relapsed/Refractory Transplant or CAR-T Therapy Eligible Diffuse B-Cell Lymphoma November 4, 2022 December 31, 2024
NCT06030258 Recruiting Phase 1/Phase 2 IN10018 Combination Therapy in Treatment-naïve ES-SCLC October 30, 2023 October 21, 2025
NCT05361395 Recruiting Phase 1 First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects With Extensive Stage Small Cell Lung Cancer (ES-SCLC) August 24, 2022 January 1, 2027
NCT02094794 Recruiting Phase 2 Total Marrow and Lymphoid Irradiation and Chemotherapy Before DSCT in Treating Patients With High-Risk ALL or AML May 12, 2014 February 28, 2025
NCT05312671 Recruiting Phase 2 Atezolizumab Plus Etoposide and Platinum in Small Cell Bladder Cancer June 27, 2022 June 2027
NCT05955261 Recruiting Phase 2 A Study of Venetoclax in Combination With Conventional Chemotherapy in Pediatric Patients With Acute Myeloid Leukemia July 25, 2023 March 2034
NCT05298423 Recruiting Phase 3 Study of Pembrolizumab/Vibostolimab (MK-7684A) in Combination With Concurrent Chemoradiotherapy Followed by Pembrolizumab/Vibostolimab Versus Concurrent Chemoradiotherapy Followed by Durvalumab in Participants With Stage III Non-small Cell Lung Cancer (MK-7684A-006/KEYVIBE-006) May 3, 2022 September 4, 2029
NCT05294055 Recruiting Phase 2 Mecapegfilgrastim With Chemotherapy for Peripheral Blood Stem Cell Mobilization in MM and Lymphoma April 26, 2022 September 30, 2024
NCT05270057 Recruiting Phase 1 Loncastuximab Tesirine in Combination With DA-EPOCH-R in Patients With Previously Untreated Aggressive B-cell Lymphoid Malignancies January 26, 2023 May 2026
NCT05221645 Recruiting Phase 2 Pembrolizumab in Combination With R-ICE Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma June 27, 2022 December 1, 2025
NCT02372409 Recruiting Phase 2 Using MRI-Guided Laser Heat Ablation to Induce Disruption of the Peritumoral Blood Brain Barrier to Enhance Delivery and Efficacy of Treatment of Pediatric Brain Tumors August 14, 2015 August 31, 2030
NCT05936086 Recruiting N/A A Randomized Controlled Study of High-dose Cyclophosphamide Induction Therapy in Adult Patients With HLH April 20, 2023 May 20, 2027
NCT02797717 Recruiting N/A Treatment for Classical Hodgkin Lymphoma in Children and Adolescents November 2015 December 2027
NCT06221683 Recruiting Phase 2 Clinical Study of Induction Therapy Options Based on Molecular Subtyping and MRD in Children and Adolescents With AML March 2024 December 2029
NCT02393157 Recruiting Phase 2 Obinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHL August 21, 2015 December 2024
NCT05142696 Recruiting Phase 1/Phase 2 A Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and Atezolizumab July 13, 2022 May 3, 2028
NCT04546399 Suspended Phase 2 A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL) December 4, 2020 June 30, 2028
NCT04231877 Suspended Phase 1 Polatuzumab Vedotin and Combination Chemotherapy for the Treatment of Untreated Aggressive Large B-cell Lymphoma October 27, 2020 December 1, 2031
NCT00072280 Terminated Phase 2 Surgery and/or Chemotherapy in Treating Children With Infantile, Congenital, or Childhood Fibrosarcoma November 2004 March 2008
NCT01411098 Terminated Phase 1 Radiation Therapy, Cisplatin, and Etoposide in Treating Patients With Non-small Cell Lung Cancer That Cannot Be Removed by Surgery October 2011
NCT01904643 Terminated Phase 1 Lenalidomide and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia February 2014 July 18, 2015
NCT01408043 Terminated N/A Etoposide, Filgrastim, and Plerixafor in Improving Stem Cell Mobilization in Treating Patients With Non-Hodgkin Lymphoma October 2011 May 2016
NCT01390584 Terminated Phase 2 Chemotherapy Based on PET Scan in Treating Patients With Stage I or Stage II Hodgkin Lymphoma May 24, 2013 May 18, 2018
NCT01342887 Terminated Phase 1/Phase 2 Cyclosporine, Pravastatin Sodium, Etoposide, and Mitoxantrone Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia April 2011 March 2012
NCT01260714 Terminated Phase 1 Azacitidine, Mitoxantrone Hydrochloride, and Etoposide in Treating Older Patients With Poor-Prognosis Acute Myeloid Leukemia December 2010 June 2015
NCT01258634 Terminated Phase 1 A Study of Pre-Operative Treatment of Newly-Diagnosed, Surgically-Resectable Osteosarcoma With Doxorubicin, Ifosfamide, Etoposide, and Cisplatin With Early Metabolic Assessment of Response July 2010 November 2011
NCT01222572 Terminated Phase 1/Phase 2 Stereotactic Boost for Locally Advanced Non-Small Cell Lung Cancer December 2010 October 2012
NCT01220297 Terminated Phase 2 Sirolimus & Mycophenolate Mofetil as GvHD Prophylaxis in Myeloablative, Matched Related Donor HCT August 2006 August 2011
NCT01032070 Terminated Phase 2 Erlotinib Versus Oral Etoposide in Patients With Recurrent or Refractory Pediatric Ependymoma September 27, 2010 November 26, 2012
NCT01027923 Terminated Phase 1 IV Plerixafor With Mitoxantrone Etoposide and Cytarabine for Acute Myeloid Leukemia (AML) May 2010 September 2011
NCT01014767 Terminated Phase 3 Intercontinental Multidisciplinary Registry and Treatment Optimization Study for Choroid Plexus Tumors November 2009 January 2014
NCT02043587 Terminated Phase 2 Chemotherapy With Liposomal Cytarabine CNS Prophylaxis for Adult Acute Lymphoblastic Leukemia & Lymphoblastic Lymphoma January 2014 April 14, 2022
NCT00981799 Terminated Phase 1/Phase 2 Trial of Nelarabine, Etoposide and Cyclophosphamide in Relapsed T-cell ALL and T-cell LL June 2010 July 18, 2016
NCT00977561 Terminated Phase 2 A Study Of Cisplatin (Or Carboplatin) And Etoposide With Or Without Figitumumab (CP-751,871) In Patients With Extensive-Stage Small Cell Lung Cancer April 2010 October 2011
NCT00960063 Terminated Phase 1 A Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Pediatric Participants With Advanced Solid Tumors (P05883, MK-7454-006) November 11, 2009 December 22, 2010
NCT02116959 Terminated Phase 1 Alternating Systemic Chemotherapy and Intra-Arterial Melphalan (IAM) Chemotherapy in Children With Intra-Ocular Retinoblastoma July 23, 2014 May 25, 2019
NCT00939653 Terminated Phase 2 T2007-002 Clofarabine, Etoposide, Cyclophosphamide in Relapsed Acute Myelogenous Leukemia (AML) July 10, 2009 July 15, 2011
NCT00924209 Terminated Phase 2 A Phase II Study of Neo-Adjuvant Gemcitabine, Cisplatin and Bevacizumab in Stage IIIA (N2) Non-Squamous Cell Non-Small Cell Lung Cancer March 2009 September 2011
NCT00920153 Terminated Phase 3 Three Different Therapy Regimens in Treating Patients With Previously Untreated Hodgkin Lymphoma May 2008 March 2016
NCT00882076 Terminated Phase 1 Clofarabine, Etoposide, and Mitoxantrone for Relapsed and Refractory Acute Leukemias March 2009 March 2011
NCT00811993 Terminated Phase 1 A Study of R1507 in Combination With Multiple Standard Chemotherapy Treatments in Patients With Advanced Solid Tumors February 2009 December 2012
NCT00810017 Terminated Phase 2 Phase 2 Study of Trastuzumab and Etoposide for Her2 Positive Breast Cancer February 2009 June 2010
NCT00809341 Terminated Phase 2 R-ICE and High-Dose Cyclophosphamide With PET/CT for Diffuse Large B-Cell Non-Hodgkin's Lymphoma January 2009 April 2014
NCT00808899 Terminated Phase 2 Neuroblastoma Protocol 2008: Therapy for Children With Advanced Stage High Risk Neuroblastoma December 2008 July 2009
NCT00807755 Terminated Phase 1 Everolimus, Carboplatin, and Etoposide in Treating Patients With Small Cell Lung Cancer or Other Advanced Solid Tumors March 2009 December 2011
NCT00726986 Terminated Phase 2 Sorafenib, Cisplatin, and Etoposide in Treating Patients With Extensive-Stage Small Cell Lung Cancer July 2008 July 2012
NCT00660036 Terminated Phase 1 Phase I/II Study of Mitoxantrone, Etoposide and Gemtuzumab Ozogamicin for Acute Myeloid Leukemia September 2008 April 2011
NCT00632827 Terminated Phase 2 Treatment of PTCL With Aggressive Induction Therapy Followed by Autologous SCT Using Denileukin Diftitox (Ontak) July 1, 2008 June 23, 2016
NCT00630565 Terminated Phase 2/Phase 3 Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia July 26, 2006 July 28, 2022
NCT00623077 Terminated Phase 1 MT2004-30: Tomotherapy for Solid Tumors August 2005 October 2016
NCT02349178 Terminated Phase 2 Bridging Study to Eliminate Presence of MRD for Acute Leukemia Before HCT December 8, 2014 March 16, 2017
NCT02359162 Terminated Phase 3 Efficacy and Safety Study of P-Gemox vs.EPOCH as First-line Chemotherapy to Treat NK/T-cell Lymphoma With Early Stage May 2015 June 2017
NCT02366663 Terminated Phase 3 BEAM vs. 90-Yttrium Ibritumomab Tiuxetan (Zevalin®)/BEAM With ASCT for Relapsed DLBCL January 2015 October 2016
NCT00540995 Terminated Phase 1/Phase 2 Busulfan, Etoposide, and Intensity-Modulated Radiation Therapy Followed By Donor Stem Cell Transplant in Treating Patients With Advanced Myeloid Cancer June 11, 2007 August 9, 2011
NCT00539500 Terminated Phase 2/Phase 3 Autologous Stem Cell Rescue With CD133+ Selected Cells in High-Risk Neuroblastoma October 2007 September 5, 2012
NCT00537511 Terminated Phase 1/Phase 2 A Phase I/II Study to Determine the Maximum Tolerated Dose (MTD) and Safety of CC-4047 (Pomalidomide) Administered in Conjunction With Cisplatin and Etoposide February 1, 2008 December 1, 2010
NCT00529503 Terminated Phase 2 A Randomized Phase IIb Placebo-Controlled Study of R-ICE Chemotherapy With and Without SGN-40 for Patients With DLBCL September 2007 May 2011
NCT00505921 Terminated Phase 2 Autologous and Allogenic Transplantation With Campath-1H for T-Cell Lymphoma March 2003 November 2009
NCT00500890 Terminated Phase 3 Treatment of Tumors of the Choroid Plexus Epithelium September 2, 2005 December 14, 2017
NCT00482053 Terminated Phase 2 Phase 2 Poor Risk DLBCL of TLI and ATG Followed by Matched Allogeneic HT as Consolidation to Autologous HCT October 2006 May 2010
NCT02483000 Terminated Phase 1 Anti-CD20 Radioimmunotherapy Before Chemotherapy and Stem Cell Transplant in Treating Patients With High-Risk B-Cell Malignancies February 1, 2017 September 2, 2020
NCT00481832 Terminated Phase 2 Autologous Followed by Non-myeloablative Allogeneic Transplantation for Non-Hodgkin's Lymphoma January 2007 March 30, 2017
NCT00417248 Terminated Phase 1/Phase 2 Cisplatin/Etoposide/Radiotherapy Followed by Consolidation Sorafenib for Inoperable Stage III Non-Small Cell Lung Cancer June 2007 April 2008
NCT02518750 Terminated Phase 2 Re-Induction Therapy for Relapsed Pediatric T-Cell Acute Lymphoblastic Leukemia or Lymphoma November 23, 2016 March 11, 2018
NCT00354107 Terminated Phase 1/Phase 2 Ifosfamide, Carboplatin, Etoposide, and SGN-30 in Treating Young Patients With Recurrent Anaplastic Large Cell Lymphoma January 2007 January 2010
NCT00351195 Terminated Phase 2 Etoposide, Oxaliplatin and Capecitabine in Advanced Hepatocellular Carcinoma (HCC) February 2006 April 2007
NCT02592876 Terminated Phase 2 Treatment Study of Denintuzumab Mafodotin (SGN-CD19A) Plus RICE Versus RICE Alone for Diffuse Large B-Cell Lymphoma October 2015 April 20, 2018
NCT02631252 Terminated Phase 1 Phase I Study of Mitoxantrone and Etoposide Combined With Hydroxychloroquine, for Relapsed Acute Myelogenous Leukemia August 18, 2016 October 2, 2017
NCT00281879 Terminated Phase 2 Donor Stem Cell Transplant or Donor White Blood Cell Infusions in Treating Patients With Hematologic Cancer February 2006 March 2008
NCT02653196 Terminated Early Phase 1 A Multi-Institutional Pilot Study of Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Malignant Neuro-Epithelial and Other Solid Tumors September 2015 August 2017
NCT02703272 Terminated Phase 3 A Safety and Efficacy Study of Ibrutinib in Pediatric and Young Adult Participants With Relapsed or Refractory Mature B-cell Non-Hodgkin Lymphoma July 1, 2016 June 11, 2021
NCT02722369 Terminated Phase 2 STUDY 15 - Comparing Gemcitabine/Carboplatin and Hydroxychloroquine Versus Carboplatin/Etoposide Therapy Alone in Small Cell Lung Cancer (SCLC) March 14, 2017 March 12, 2021
NCT02748889 Terminated Phase 1/Phase 2 Carboplatin Plus Etoposide With or Without MPDL3280A in Untreated Extensive Stage Small Cell Lung Cancer March 2016 May 9, 2017
NCT02768558 Terminated Phase 3 Cisplatin and Etoposide Plus Radiation Followed By Nivolumab/Placebo For Locally Advanced NSCLC October 17, 2016 January 23, 2019
NCT02773732 Terminated Phase 1/Phase 2 Clinical Trial of Oral Ciprofloxacin and Etoposide in Subjects With Resistant Acute Myeloid Leukemia (AML)(UF-AML-CE-101) December 16, 2016 November 15, 2021
NCT00253552 Terminated N/A G-CSF-Treated Donor Bone Marrow Transplant in Treating Patients With Hematologic Disorders May 2004 May 2006
NCT00225173 Terminated Phase 2 Combination Chemotherapy +/- Radiation in High Risk Hodgkin's Disease October 2001 September 2006
NCT02819999 Terminated Phase 1 A Study of Rovalpituzumab Tesirine (SC16LD6.5) in the Frontline Treatment of Patients With Extensive Stage Small Cell Lung Cancer October 2016 May 31, 2019
NCT00126191 Terminated Phase 2 Intensive Chemotherapy and Rituximab in the Treatment of Burkitt Lymphoma July 2005 June 2011
NCT02899728 Terminated Phase 2 Olaparib, Cediranib Maleate, and Standard Chemotherapy in Treating Patients With Small Cell Lung Cancer March 30, 2018 March 17, 2020
NCT02934503 Terminated Phase 2 Study of Pembrolizumab and Chemotherapy With or Without Radiation in Small Cell Lung Cancer (SCLC) January 23, 2017 October 1, 2019
NCT00124644 Terminated Phase 1 Combination Chemotherapy and Tipifarnib in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia March 2006 January 2008
NCT00101205 Terminated Phase 1 Oxaliplatin, Ifosfamide and Etoposide in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma November 2004
NCT02987998 Terminated Phase 1 Neoadjuvant Chemoradiation Plus Pembrolizumab Followed By Consolidation Pembrolizumab in NSCLC May 19, 2017 November 28, 2022
NCT00074490 Terminated Phase 2 Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers January 1, 2004 August 16, 2017
NCT00074165 Terminated Phase 2 Treating Patients With Recurrent PCNSL With Carboplatin/BBBD and Adding Rituxan To The Treatment Regimen January 2003 December 2010
NCT00060385 Terminated Phase 2/Phase 3 Combination Chemotherapy With or Without Etoposide in Treating Older Patients With Non-Hodgkin's Lymphoma March 2003
NCT00058461 Terminated Phase 2 Combination Chemotherapy and Rituximab in Treating Young Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or Acute Lymphoblastic Leukemia November 2003
NCT03041311 Terminated Phase 2 Carboplatin, Etoposide, and Atezolizumab With or Without Trilaciclib (G1T28), a CDK4/6 Inhibitor, in Extensive-Stage SCLC June 29, 2017 October 29, 2020
NCT00045617 Terminated Phase 2 S0122: Combination Chemotherapy, Radiation Therapy, and Vaccine Therapy in Limited-Stage Small Cell Lung Cancer January 2003 May 2003
NCT00042835 Terminated Phase 1 Erlotinib and Radiation Therapy Plus Combination Chemotherapy in Treating Patients With Inoperable Stage III Non-Small Cell Lung Cancer May 2002
NCT00031590 Terminated Phase 2 Low-Dose Radiation and Combination Chemotherapy Following Surgery in Children With Newly Diagnosed Medulloblastoma April 2001 May 2011
NCT03116971 Terminated Phase 1 Phase Ib/II Study of M3814 With Etoposide and Cisplatin in Small Cell Lung Cancer (SCLC) Extensive Disease (ED) May 25, 2017 March 1, 2018
NCT00021112 Terminated Phase 2 Combination Chemotherapy Plus Radiation Therapy Followed by Surgery in Treating Patients With Stage IIIB Non-Small Cell Lung Cancer April 2001
NCT00014313 Terminated Phase 2 Chemotherapy in Treating Patients With Metastatic Ewing's Sarcoma or Primitive Neuroectodermal Tumor January 2001
NCT00006708 Terminated Phase 3 S0019 Combination Chemotherapy With or Without Rituximab in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma October 2000 November 2006
NCT00006054 Terminated N/A Allogeneic Bone Marrow Transplantation in Patients With Primary Immunodeficiencies March 2000 December 2002
NCT03735446 Terminated Phase 1 Prexasertib in Combination With MEC in Relapsed/Refractory AML and High Risk MDS - a Phase I Trial January 18, 2019 March 29, 2019
NCT00006032 Terminated Phase 2 Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Women With Metastatic Breast Cancer March 2000 April 2001
NCT00005987 Terminated Phase 2 Filgrastim Compared With Sargramostim Plus Chemotherapy, Peripheral Stem Cell Transplantation, and Interferon Alfa in Treating Patients With Multiple Myeloma August 2000 July 2003
NCT00005834 Terminated Phase 3 S9922 Combination Chemo Plus Filgrastim With or Without Thalidomide in Refractory Multiple Myeloma April 2000 November 2007
NCT03840902 Terminated Phase 2 M7824 With cCRT in Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) April 16, 2019 February 17, 2023
NCT00005612 Terminated Phase 1/Phase 2 Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Ovarian Epithelial Cancer August 1999 February 2004
NCT03860844 Terminated Phase 2 Isatuximab in Combination With Chemotherapy in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia August 6, 2019 May 26, 2023
NCT03864419 Terminated Phase 1 Rituximab Hyaluronidase in Combination With Chemotherapy in Treating Aggressive B-cell Lymphoma in Uganda October 24, 2019 July 26, 2023
NCT00005090 Terminated Phase 3 S9901 Combination Chemotherapy With or Without Peripheral Stem Cell Transplantation in Treating Men With Stage III or Stage IV Hodgkin's Disease April 2000 May 2005
NCT00003852 Terminated Phase 2 Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Germ Cell Tumors March 1998 March 2000
NCT04189952 Terminated Phase 2 Acalabrutinib in Combination With R-ICE For Relapsed or Refractory Lymphoma September 22, 2020 March 1, 2022
NCT04326439 Terminated Phase 2 AflacLL1901 (CHOA-AML) January 24, 2020 March 15, 2022
NCT04356690 Terminated Phase 2 Etoposide in Patients With COVID-19 Infection May 8, 2020 July 1, 2022
NCT04372927 Terminated Phase 2 ADMIRAL Trial: Adaptive Mediastinal Radiation With Chemo-Immunotherapy December 10, 2021 April 23, 2022
NCT04422210 Terminated Phase 1 A Study Evaluating The Safety, Tolerability, Pharmacokinetics, And Efficacy Of Venetoclax In Combination With Atezolizumab, Carboplatin, And Etoposide In Participants With Untreated Extensive-Stage Small Cell Lung Cancer (ES-SCLC). September 22, 2020 November 6, 2020
NCT00003380 Terminated Phase 1 Liposomal Doxorubicin and Etoposide in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, or Peritoneal Cancer May 1998
NCT04610684 Terminated Phase 2 Chemotherapy and Atezolizumab for Patients With Extensive Stage Small Cell Lung Cancer (SCLC) With Untreated, Asymptomatic Brain Metastases January 5, 2021 September 20, 2022
NCT00003194 Terminated Phase 1 Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory Solid Tumors July 1997 December 19, 2002
NCT00003113 Terminated Phase 2 Oral Combination Chemotherapy in Treating Elderly Patients With Intermediate or High-Grade Non-Hodgkin's Lymphomas July 1997 December 2002
NCT00002961 Terminated Phase 3 Chemotherapy With or Without Total-Body Irradiation Prior to Bone Marrow Transplantation in Treating Children With Acute Lymphoblastic Leukemia October 1995 February 2001
NCT04870112 Terminated Phase 1 A Study to Evaluate Subcutaneous Durvalumab in Patients With Non-Small Cell Lung Cancer and Small Cell Lung Cancer June 28, 2021 August 30, 2023
NCT00002478 Terminated Phase 2 Etoposide in Treating Patients With Advanced Ovarian or Cervical Cancer June 1993
NCT01722292 Terminated Phase 1/Phase 2 A Study of LY2940680 in Small Cell Lung Cancer January 2013 February 2015
NCT01746173 Terminated Phase 2 CHOEP + High Dose Therapy + Auto SCT for T-Cell Lymphoma July 2013 October 2014
NCT01653418 Terminated Phase 2 Phase II Study of V-BEAM Conditioning Regimen Prior to Second Autologous Stem Cell Transplantation September 2012 December 2013
NCT01573338 Terminated Phase 1/Phase 2 Clinical Study to Evaluate the Maximum Tolerated Dose of BAY1000394 When Given Together With Chemotherapy and the Effectiveness of This Combination Treatment in Shrinking a Specific Type of Lung Tumors (Small Cell Lung Cancer) February 25, 2013 June 23, 2016
NCT01822496 Terminated Phase 2 Erlotinib Hydrochloride or Crizotinib and Chemoradiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer November 4, 2013 June 4, 2018
NCT01565772 Terminated Phase 1 Proton Radiation Therapy With Cisplatin and Etoposide Followed by Surgery in Stage III Non-Small Cell Lung Cancer March 2012 June 2015
NCT01548573 Terminated Phase 2 Tandem Auto Transplantation in Myeloma Patients With <12 Months of Prior Treatment May 2012 August 2014
NCT01500161 Terminated Phase 2 Pooled Unrelated Donor Umbilical Cord Blood Transplant For Hematologic Malignancy Needing Allogeneic Stem Cell Transplant Without Related HLA-Match November 2011 November 2013
NCT01859741 Terminated Phase 1/Phase 2 A Phase 1b/2 Study of OMP-59R5 (Tarextumab) in Combination With Etoposide and Platinum Therapy January 7, 2012 May 8, 2017
NCT03553238 Unknown status Phase 2/Phase 3 Precision Diagnosis Directing HDACi Chidamide Target Therapy for Adult ETP-ALL February 14, 2016 August 30, 2020
NCT04061772 Unknown status Phase 2 A Study of Bortezomib Combined With CHEP in Peripheral T Cell Lymphoma August 12, 2019 December 5, 2021
NCT04077905 Unknown status Phase 3 Pegylated Liposomal Doxorubicin as a Induction Therapy for Lymphoma Induced Hemophagocytic Lymphohistiocytosis. August 31, 2019 July 31, 2021
NCT00003643 Unknown status Phase 2/Phase 3 Combination Chemotherapy in Treating Men With Germ Cell Cancer October 1998
NCT00003602 Unknown status Phase 3 Combination Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia March 1998
NCT00360750 Unknown status N/A Chemotherapy With or Without Radiation Therapy or Observation in Treating Young Patients With Advanced Retinoblastoma Who Have Undergone Surgery to Remove the Eye September 2005
NCT00379457 Unknown status Phase 3 Combination Chemotherapy in Treating Young Patients With Nonmetastatic Rhabdomyosarcoma June 2006
NCT00392886 Unknown status Phase 3 Combination Chemotherapy With or Without Etoposide Followed By an Autologous Stem Cell Transplant in Treating Young Patients With Previously Untreated Malignant Brain Tumors March 2004
NCT00416676 Unknown status Phase 3 Combination Chemotherapy and Surgery With or Without Radiation Therapy in Treating Patients With Stage 2 or Stage 3 Neuroblastoma
NCT01468740 Unknown status Phase 2 Prospective Study on HIV-related Hodgkin Lymphoma March 2004 July 2012
NCT02348450 Unknown status Phase 4 Irinotecan Plus Cisplatin Compared With Etoposide Plus Cisplatin for Extensive Stage Small-cell Lung Cancer February 2015 December 2018
NCT00550992 Unknown status N/A Different Therapies in Treating Infants With Newly Diagnosed Acute Leukemia January 2006
NCT00616785 Unknown status Phase 2 Combination Chemotherapy and Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery June 2007
NCT00669812 Unknown status Phase 2 High-Dose Chemotherapy Given Together With Peripheral Blood Stem Cell Transplant in Treating Patients With Intestinal T-Cell Lymphoma February 2008
NCT00720447 Unknown status Phase 2 Donor Stem Cell Transplant in Treating Patients With Mantle Cell Lymphoma November 2008
NCT03700359 Unknown status Phase 2 A Study of Lobaplatin/Etoposide With or Without Anlotinib Maintenance Therapy in Patients With ES-SCLC March 1, 2019 November 29, 2021
NCT03711305 Unknown status Phase 3 Study of Carboplatin Plus Etoposide With or Without SHR-1316 in Participants With Untreated Extensive-Stage (ES) Small Cell Lung Cancer (SCLC) December 30, 2018 December 2023
NCT03617432 Unknown status Phase 2 Chidamide Combined With CHOPE Regimen for Peripheral T-cell Lymphoma Patients August 28, 2018 September 30, 2022
NCT00764907 Unknown status Phase 3 Risk-Adjusted Combination Chemotherapy in Treating Young Patients With Acute Lymphoblastic Leukemia November 2002
NCT03583424 Unknown status Phase 1/Phase 2 Venetoclax, Carmustine, Etoposide, Cytarabine, and Melphalan Before Stem Cell Transplant in Treating Participants With Relapsed or Refractory Non-Hodgkin Lymphoma September 10, 2018 December 31, 2022
NCT03742115 Unknown status Phase 3 Etoposide in the First-line Treatment of Adult EBV-HLH December 1, 2018 December 1, 2020
NCT00006045 Unknown status Phase 3 Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With Refractory or Relapsed Acute Myelogenous Leukemia March 2000
NCT00006056 Unknown status N/A Pilot Study of Unrelated Donor Hematopoietic Stem Cell Transplantation in Patients With Life Threatening Hemophagocytic Disorders March 2000
NCT02179528 Unknown status Phase 2 Study of Small Doses of Etoposide as Maintenance Treatment in Small Cell Lung Cancer(SCLC) September 2014 September 2017
NCT00002481 Unknown status Phase 2 Combination Chemotherapy and Radiation Therapy Plus Bone Marrow Transplantation in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma March 1990
NCT00908180 Unknown status Phase 2 Carmustine, Etoposide, Cytarabine, Melphalan, and Alemtuzumab Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma July 2009
NCT00002488 Unknown status Phase 2 Combination Chemotherapy in Treating Patients With Intermediate-Grade or High-Grade Non-Hodgkin's Lymphoma Who Have Not Responded to Anthracycline-Containing Combination Chemotherapy December 1991
NCT03923179 Unknown status Phase 2 Phase II Clinical Study of Pyrotinib Combined With Etoposide to Treat HER2-positive Advanced Breast Cancer April 19, 2019 December 31, 2021
NCT00004903 Unknown status Phase 2 Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma October 1999
NCT00004128 Unknown status Phase 3 Combination Chemotherapy, Interleukin-2, and Peripheral Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia September 1999
NCT03963193 Unknown status Phase 2 Etoposide/Cisplatin Compared With Irinotecan/Cisplatin for Advanced Gastrointestinal Neuroendocrine Tumor G3 Type June 1, 2019 June 1, 2021
NCT00004086 Unknown status Phase 1 Radiolabeled Monoclonal Antibody, Combination Chemotherapy, and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory B-Cell Cancer June 1997
NCT02099188 Unknown status Phase 2 Multidisciplinary Approach for Poor Prognosis Sinonasal Tumors in Inoperable Patients November 2013 January 2024
NCT00003815 Unknown status Phase 3 Chemotherapy and Radiation Therapy Plus Bone Marrow Transplantation in Treating Patients With Aggressive Non-Hodgkin's Lymphoma June 1994
NCT04000295 Unknown status Phase 3 Apatinib and Etoposide Capsule Versus Weekly Paclitaxel in Patients With Platinum Resistant Ovarian Cancer August 16, 2019 July 2022
NCT00003728 Unknown status Phase 3 Combination Chemotherapy Plus Steroid Therapy in Treating Children With Acute Lymphoblastic Leukemia or Lymphoblastic Non-Hodgkin's Lymphoma December 1998
NCT03564704 Unknown status Phase 2/Phase 3 Precision Diagnosis Directing HDACi Chidamide Target Therapy for Adult T-LBL/ALL February 14, 2016 May 30, 2021
NCT00003696 Unknown status Phase 3 Combination Chemotherapy in Treating Patients Who Have Extensive-Stage Small Cell Lung Cancer October 1998
NCT00003583 Unknown status Phase 2 Amifostine to Prevent Side Effects in Patients Who Are Receiving Chemotherapy and Radiation Therapy for Limited-Stage Small Cell Lung Cancer June 1997
NCT04189094 Unknown status Phase 2 Chemoradiotherapy With or Without Sintilimab in Limited-stage SCLC January 1, 2020 July 1, 2023
NCT02099175 Unknown status Phase 2 Multidisciplinary Approach for Poor Prognosis Sinonasal Tumors in Operable Patients November 2013 January 2024
NCT00011921 Unknown status Phase 3 Chemotherapy Followed by Peripheral Stem Cell or Bone Marrow Transplant Compared With Chemotherapy Alone in Treating Patients With Small Cell Lung Cancer September 1997
NCT04234607 Unknown status Phase 3 A Study of TQB2450 or Placebo Combined With Anlotinib, Etoposide and Carboplatin Versus Etoposide and Carboplatin in Subjects With Extensive Small Cell Lung Cancer (ETER701) January 2020 December 2022
NCT00003578 Unknown status Phase 3 High Dose Chemotherapy With or Without Bone Marrow Transplantation in Treating Patients With Intermediate- or High-Grade Non-Hodgkin's Lymphoma January 1993
NCT00003558 Unknown status Phase 3 Chemotherapy in Treating Patients With Cancer of Unknown Primary Origin August 1998
NCT00012311 Unknown status Phase 2 Chemotherapy Plus Peripheral Stem Cell Transplantation Compared With Chemotherapy Alone in Treating Women With Stage IV Breast Cancer January 2000
NCT00016887 Unknown status Phase 3 Chemotherapy Followed by Radiation Therapy and Peripheral Stem Cell Transplant Compared With Chemotherapy Plus Interferon Alfa in Treating Patients With Stage III or Stage IV Mantle Cell Lymphoma December 2000
NCT02015728 Unknown status N/A Selecting Patient-Specific Biologically Targeted Therapy for Pediatric Patients With Refractory Or Recurrent Brain Tumors December 2013 December 2017
NCT00003423 Unknown status Phase 3 Combination Chemotherapy in Treating Children With Non-Hodgkin's Lymphoma May 1995
NCT04405375 Unknown status Phase 2 GPED Regimen for Relapsed/Refractory or Advanced ENKTCL March 21, 2020 April 30, 2023
NCT01857453 Unknown status Phase 2 Interest of a Dose Decrease for Radiotherapy Associated With Chemotherapy for Treatment of Standard Risk Adult Medulloblastomas April 10, 2013 December 2021
NCT03367143 Unknown status Phase 2 Lenalidomide Plus ICE in the Treatment of Refractory and Relapsed DLBCL December 2016 December 2020
NCT01492556 Unknown status Phase 2 Study of Etoposide in Treating Patients With Recurrent or Metastatic Breast Cancer December 2011 June 2015
NCT00020566 Unknown status Phase 3 Combination Chemotherapy With or Without Peripheral Stem Cell Transplantation, Radiation Therapy, and/or Surgery in Treating Patients With Ewing's Sarcoma February 2001
NCT03321890 Unknown status Phase 2 Chidamide Combined With PECM in Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL) March 7, 2017 December 31, 2020
NCT03298074 Unknown status Phase 2 Apatinib Plus Etoposide Versus Etoposide Alone for Platinum-resistant Recurrent Ovarian Cancer October 2017 April 2019
NCT00024193 Unknown status Phase 2 Chemotherapy and Surgery Followed by Peripheral Stem Cell Transplantation in Treating Patients With Metastatic Neuroblastoma April 1999
NCT00025064 Unknown status Phase 2 Combination Chemotherapy With or Without Radiation Therapy and Peripheral Stem Cell Transplant in Treating Children With Hodgkin's Lymphoma January 2000
NCT00025103 Unknown status Phase 2 Chemotherapy Followed by Surgery and Radiation Therapy With or Without Stem Cell Transplant in Treating Patients With Relapsed or Refractory Wilms' Tumor or Clear Cell Sarcoma of the Kidney May 2001
NCT01172912 Unknown status Phase 2 High-Dose Chemotherapy and Stem Cell Transplant in Treating Patients With Metastatic Germ Cell Tumors That Have Not Responded to First-Line Therapy October 2010
NCT00003284 Unknown status Phase 2 High-Dose Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Lung Cancer January 1998
NCT00025324 Unknown status Phase 2 Chemotherapy, Surgery, Radiation Therapy and Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Primary CNS Germ Cell Tumors December 2000
NCT00003262 Unknown status Phase 2 Combination Chemotherapy in Treating Patients With Hodgkin's Disease and HIV Infection May 1997
NCT00025402 Unknown status Phase 3 Chemotherapy and Biological Therapy With or Without Bone Marrow or Peripheral Stem Cell Transplant in Treating Patients With Chronic Myelogenous Leukemia July 1997
NCT00025636 Unknown status Phase 3 Combination Chemotherapy and Peripheral Stem Cell Transplant in Treating Patients With Relapsed Hodgkin's Lymphoma July 2001
NCT04684017 Unknown status Phase 2 Anlotinib Plus Etoposide and Carboplatin as First-line Treatment for Extensive-stage Small Cell Lung Cancer May 1, 2019 January 1, 2022
NCT00030719 Unknown status Phase 3 Combination Chemotherapy With or Without Filgrastim Before Surgery, High-Dose Chemotherapy, and Radiation Therapy Followed by Isotretinoin With or Without Monoclonal Antibody in Treating Patients With Neuroblastoma December 2001
NCT03071822 Unknown status Phase 4 Combination Chemotherapy Including Cisplatin, Ifosfamide, Gemcitabine, L-asparaginase, Etoposide and Dexamethasone as Treatment of Newly Diagnosed and Relapsed/Refractory Peripheral T Cell Lymphomas February 24, 2017 February 28, 2022
NCT04696939 Unknown status Phase 2 Combined Atezolizumab and Chemotherapy (Carboplatin Plus Etoposide) in Neoadjuvant Treating Limited-Stage Small Cell Lung Cancer Patients January 2021 October 2023
NCT00032149 Unknown status Phase 1/Phase 2 Combination Chemotherapy Plus Filgrastim in Treating Patients With HIV-Related Non-Hodgkin's Lymphoma October 2001
NCT00041210 Unknown status Phase 3 Combination Chemotherapy in Treating Patients With Previously Untreated Advanced Hodgkin's Lymphoma October 2001
NCT03061656 Unknown status Phase 2 Tandem High Dose Chemotherapy With 131I-MIBG Treatment in High Risk Neuroblastoma January 1, 2009 December 31, 2018
NCT00003053 Unknown status Phase 3 Combination Chemotherapy in Treating Patients With Stage I, II, or IIIA Non-small Cell Lung Cancer That Has Been Surgically Removed January 1994
NCT04740021 Unknown status Phase 2 Study of LP002 in Combination With Chemotherapy for Patients With Extensive Stage Small Cell Lung Cancer December 2, 2020 August 1, 2022
NCT00002987 Unknown status Phase 3 Combination Chemotherapy Given With Radiation Therapy or Radiation Therapy Alone in Treating Patients With Early-Stage Hodgkin's Disease January 1997
NCT00047138 Unknown status Phase 3 Chemotherapy Before and After Surgery in Treating Children With Wilm's Tumor January 2001
NCT01555710 Unknown status Phase 3 Study of Palifosfamide-tris in Combination With Carboplatin and Etoposide in Chemotherapy Naïve Patients With Extensive-Stage Small Cell Lung Cancer (The MATISSE Study) May 2012 June 2015
NCT00002926 Unknown status Phase 3 Combination Chemotherapy With or Without Peripheral Stem Cell Transplantation in Treating Patients With Myelodysplastic Syndrome or Acute Myelogenous Leukemia December 1996
NCT03018626 Unknown status Phase 3 R-ACVBP and DA-EPOCH-R in Patients With Non-GCB DLBCL July 27, 2017 January 2021
NCT00083083 Unknown status Phase 2 Fludeoxyglucose F18 Positron Emission Tomography Imaging In Assessing Patients Before and After Treatment for Locally Advanced Non-Small Cell Lung Cancer March 2005
NCT02987244 Unknown status Phase 1/Phase 2 Chidamide Plus CHOEP Combined With Upfront ASCT in Untreated Peripheral T-cell Lymphoma March 2016 March 2023
NCT00002905 Unknown status Phase 2 Combination Chemotherapy in Treating Patients With HIV-Related Non-Hodgkin's Lymphoma June 1995
NCT04917250 Unknown status Phase 2 GPED for Patients With Relapsed/Refractory or Advanced NK/T-cell Lymphoma March 20, 2020 August 31, 2021
NCT02949258 Unknown status Phase 2 Neoadjuvant Chemotherapy With SEEOX Regimen for Borrmann Type 4 Gastric Cancer January 2017 January 2021
NCT00002887 Unknown status Phase 1 Hydroxyurea Plus Combination Chemotherapy in Patients With Non-small Cell Lung Cancer July 1995
NCT00002858 Unknown status Phase 3 Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Small Cell Lung Cancer March 1993
NCT00002701 Unknown status Phase 3 Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Patients With Acute Promyelocytic Leukemia October 1995
NCT02912702 Unknown status Phase 3 L-DEP as an Initial Treatment for EBV-HLH September 2016 September 2019
NCT00131027 Unknown status Phase 3 High-Dose Methotrexate (MTX) for Adult Acute Lymphoblastic Leukemia (ALL) September 2002 September 2011
NCT00002688 Unknown status Phase 2 Cyclosporine and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia February 1995
NCT00199147 Unknown status Phase 4 Efficacy of G-CSF-Priming in Elderly AML Patients January 2000
NCT00002658 Unknown status Phase 3 Combination Chemotherapy, Biological Therapy, and Bone Marrow Transplantation in Treating Patients With Acute Myeloid Leukemia January 1994
NCT05049473 Unknown status Phase 2 Treatment of Mature B-ALL and Burkitt Lymphoma (BL) in Adult Patients. BURKIMAB-14. January 2014 January 2024
NCT02858804 Unknown status Phase 4 EDOCH Alternating With DHAP for New Diagnosed Younger MCL January 2016 June 2020
NCT02848183 Unknown status Phase 2 Optimal Treatment Strategy Based on for Pediatric AML January 2016
NCT00002557 Unknown status Phase 2 Combination Chemotherapy in Patients With Advanced or Recurrent Mycosis Fungoides June 1993
NCT02836639 Unknown status Phase 2 BEB Conditioning Regimen for Autologous Stem-cell Transplantation(ASCT) in Non-Hodgkin's Lymphoma February 2016
NCT00002549 Unknown status Phase 3 Combination Chemotherapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Acute Myelogenous Leukemia November 1993
NCT00209222 Unknown status Phase 3 Efficacy of R-CHOP vs R-CHOP/R-DHAP in Untreated MCL July 2004 December 2014
NCT00209833 Unknown status Phase 2/Phase 3 Treatment of Adults Aged Up to 60 Years With De Novo Acute Myeloblastic Leukaemia,Secondary AML, or RAEB-T January 1999 September 2005
NCT00002532 Unknown status Phase 2 Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphocytic Leukemia January 1993
NCT00274950 Unknown status Phase 3 Observation and/or Combination Chemotherapy After Surgery or Biopsy in Treating Young Patients With Extracranial Germ Cell Tumors May 2005
NCT00002531 Unknown status Phase 2 Combination Chemotherapy in Treating Adults With Acute Lymphocytic Leukemia January 1993
NCT02784054 Unknown status Phase 2 Reduced Dose Radiotherapy Following High Dose Chemotherapy in Intracranial Non-germinomatous Germ Cell Tumor April 2014 March 2023
NCT02784015 Unknown status Phase 2 Response Based Treatment for Children With Unresectable Localized Soft Tissue Sarcoma May 2016 May 2023
NCT02782754 Unknown status Phase 2 Chemotherapy Plus Reduced Radiotherapy in Intracranial Germinoma January 2013
NCT00002516 Unknown status Phase 3 Combination Chemotherapy Plus Surgery and Radiation Therapy in Treating Patients With Ewing's Sarcoma July 1992
NCT02771743 Unknown status Phase 2 Response-based Treatment of High-risk Neuroblastoma April 2015 March 2023
NCT00276718 Unknown status N/A Etoposide, Carboplatin, and Bleomycin in Treating Young Patients Undergoing Surgery For Malignant Germ Cell Tumors April 1989
NCT02738346 Unknown status Phase 3 SCLC on the 2nd Line With Relapsed After Response to Chemotherapy GFPC 01-2013 July 2013 July 2017
NCT02733107 Unknown status Phase 2 The Efficacy and Safety of Apatinib Combined With Etoposide in Heavily Pretreated Advanced Non-small Cell Lung Cancer March 2016 December 2020
NCT00276731 Unknown status Phase 3 Combination Chemotherapy Followed By Surgery With or Without Radiation Therapy in Treating Young Patients With Stage II or Stage III Neuroblastoma March 1995
NCT00278252 Unknown status Phase 2 Etoposide in Treating Young Patients With Relapsed Ependymoma July 2001
NCT02660762 Unknown status Phase 2 Modified MRCUKALLⅫ/ECOGE2993 Regimen for ALL January 2016 January 2019
NCT02638428 Unknown status Phase 2 Genomics-Based Target Therapy for Children With Relapsed or Refractory Malignancy December 2015 December 2023
NCT00278278 Unknown status Phase 3 Combination Chemotherapy and Radiation Therapy With or Without Methotrexate in Treating Young Patients With Newly Diagnosed Gliomas September 2003
NCT02631239 Unknown status Phase 3 MESA Versus ESA in the Treatment of Early Stage NK/T-cell Lymphoma March 16, 2016 July 17, 2022
NCT02631109 Unknown status Phase 3 L-DEP Regimen as a Salvage Therapy for Refractory Epstein Barr Virus-induced Hemophagocytic Lymphohistiocytosis December 2015 November 2019
NCT00287950 Unknown status N/A Combination Chemotherapy, Surgery, and Radiation Therapy in Treating Infants With Neuroblastoma September 1992
NCT00324467 Unknown status Phase 2 Tailoring Treatment for B Cell Non-hodgkin's Lymphoma Based on PET Scan Results Mid Treatment August 2006 December 2021
NCT00334672 Unknown status Phase 3 Combination Chemotherapy Followed By Donor Stem Cell Transplant in Treating Patients With Hemophagocytic Lymphohistiocytosis March 2006
NCT02582697 Unknown status Phase 3 Accelerated v's Standard BEP Chemotherapy for Patients With Intermediate and Poor-risk Metastatic Germ Cell Tumours February 2014 July 2023
NCT02549261 Unknown status N/A Nimotuzumab in Combination With Radiochemotherapy for Patients With Stage IIIA/IIIB Non-small Cell Lung Cancer March 2011 December 2015
NCT02544425 Unknown status Phase 2 VP-16, Ifosfamide, Dexamethasone, L-asparaginase Chemotherapy in Patients With Extranodal Natural Killer T Cell Lymphoma (VIDL+ASCT) February 21, 2016 November 30, 2021
NCT04116359 Withdrawn Phase 1/Phase 2 Testing of the Addition of a New Anti-cancer Drug, Molibresib, to Chemotherapy Treatment (Etoposide and Cisplatin) for Patients With NUT Carcinoma September 18, 2020 September 18, 2020
NCT00006669 Withdrawn Phase 2 Rituximab Followed by Combination Chemotherapy in Treating Patients With Refractory or Recurrent Non-Hodgkin's Lymphoma September 1999 January 2000
NCT03531281 Withdrawn Phase 1 Human Lysozyme Goat Milk in Treating Patients With Blood Cancer Undergoing Donor Stem Cell Transplant December 30, 2018 December 30, 2022
NCT00003273 Withdrawn Phase 2 Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Brain Tumor November 1997
NCT03515707 Withdrawn Phase 2 Stem Cell Transplant to Treat Patients With Favorable or Intermediate Risk Minimal Residual Disease Negative Acute Myeloid Leukemia July 10, 2018 July 30, 2022
NCT01795430 Withdrawn N/A Whole-Body Radiation Therapy, Systemic Chemotherapy, and High-Dose Chemotherapy Followed By Stem Cell Rescue in Treating Patients With Poor-Risk Ewing Sarcoma July 2013
NCT00006126 Withdrawn Phase 1 Peripheral Stem Cell Transplantation in Treating Patients With Melanoma or Small Cell Lung, Breast, Testicular, or Kidney Cancer That is Metastatic or That Cannot Be Treated With Surgery September 1999 April 2001
NCT04203511 Withdrawn Phase 3 INCMGA00012 in Combination With Chemoradiation in Participants With Stage III Non-Small Cell Lung Cancer (POD1UM-301) July 31, 2020 January 31, 2025
NCT00009815 Withdrawn Phase 1 Combination Chemotherapy in Treating Patients With Advanced Solid Tumors December 1999
NCT01769911 Withdrawn N/A Genetically Modified Peripheral Blood Stem Cell Transplant in Treating Patients With HIV-Associated Non-Hodgkin or Hodgkin Lymphoma February 2015
NCT00006374 Withdrawn Phase 2 Combination Chemotherapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer October 1999 June 2001
NCT02538926 Withdrawn Phase 2 Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride With Asparaginase in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma July 1, 2018 July 30, 2021
NCT00972101 Withdrawn Phase 1 Infusion of Expanded Cord Blood T Cells September 2009 September 2011
NCT05161533 Withdrawn Phase 2 Hypofractionated Radiation Therapy After Durvalumab and Chemotherapy for the Treatment of Stage IV Extensive Stage Small Cell Lung Cancer, CASPIAN-RT Trial October 19, 2023 December 31, 2024
NCT00723658 Withdrawn Phase 2 S0629, Observation or Combination Chemotherapy, Bortezomib, Thalidomide, and Rituximab Followed By Two Autologous Peripheral Blood Stem Cell Transplants in Treating Patients With Waldenstrom Macroglobulinemia September 2008
NCT00983944 Withdrawn Phase 2 Rituximab and Combination Chemotherapy With or Without Bleomycin Sulfate in Treating Patients With Primary Mediastinal Large B-Cell Lymphoma September 2009 April 25, 2011
NCT02947113 Withdrawn Phase 2 Combination of Platinum Doublets and Hypofractionated Radiotherapy in NSCLC November 2017 November 2017
NCT01055301 Withdrawn Phase 2 S0833, Bortezomib, Thalidomide, Lenalidomide, Combination Chemotherapy, and Autologous Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma July 2011 July 2011
NCT02228512 Withdrawn Phase 1/Phase 2 Study of Pomalidomide Combined With Modified DA-EPOCH and Rituximab in KSHV-Associated Lymphomas August 15, 2014 May 5, 2015
NCT00005998 Withdrawn Phase 2 Peripheral Stem Cell Transplantation With Specially Treated Stem Cells in Treating Patients With Non-Hodgkin's Lymphoma or Hodgkin's Disease January 2000 March 2003
NCT01677949 Withdrawn Phase 2 Clofarabine, Cyclophosphamide and Etoposide for Minimal Residual Disease Positive Acute Leukemia December 2013 January 2016
NCT04989283 Withdrawn Phase 2 Testing the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy Treatment During Radiation Therapy for Superior Sulcus Non-small Cell Lung Cancer September 9, 2021 May 10, 2031
NCT03349346 Withdrawn Phase 1 Idelalisib With Rituximab, Ifosfamide, Carboplatin, Etoposide (RICE) in Children and Adolescents June 2019 February 2026
NCT05228249 Withdrawn Phase 1 Loncastuximab Tesirine in Combination With Chemotherapy Prior to Stem Cell Transplant for the Treatment of Recurrent or Refractory Diffuse Large B-Cell Lymphoma April 2023 October 1, 2027
NCT04521946 Withdrawn Phase 1 Chemotherapy and Donor Stem Transplant for the Treatment of Patients With High Grade Brain Cancer January 14, 2021 December 20, 2022
NCT05711628 Withdrawn Phase 3 A Trial Comparing Chemotherapy Versus Novel Immune Checkpoint Inhibitor (Pembrolizumab) Plus Chemotherapy in Treating Relapsed/Refractory Classical Hodgkin Lymphoma August 10, 2023 June 30, 2028
NCT02408042 Withdrawn Phase 1/Phase 2 Study of Pembrolizumab With Chemotherapy in Patients With Advanced Lymphoma (PembroHeme) April 2015 November 2015
NCT00310128 Withdrawn Phase 2 Combination Chemotherapy Followed by Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed or Refractory AIDS-Related Non-Hodgkin's Lymphoma February 2006
NCT03579927 Withdrawn Phase 1/Phase 2 CAR.CD19-CD28-zeta-2A-iCasp9-IL15-Transduced Cord Blood NK Cells, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Participants With B-cell Lymphoma October 3, 2019 October 3, 2019
NCT00829205 Withdrawn Phase 1/Phase 2 Se-Methyl-Seleno-L-Cysteine, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Diffuse Large B-Cell Lymphoma That Has Relapsed or Not Responded to Treatment January 2009
NCT01415765 Withdrawn Phase 1/Phase 2 MLN4924 Compared With MLN4924 Plus Chemotherapy for Large B-cell Lymphoma July 15, 2011 January 7, 2014
NCT00916669 Withdrawn Phase 2 A Randomized Study to Evaluate the Effect of Two Different Doses of Enoxaparin Sodium in Combination With Standard Chemotherapy in Patients With Stage Small Cell Lung Cancer (SCLC) July 2008
NCT00334867 Withdrawn Phase 3 Combination Chemotherapy With or Without Topotecan in Treating Patients With Newly Diagnosed Localized Ewing's Sarcoma December 2005